RESEARCH DOCUMENTS

DENNIS J. SLAMON, M.D., Ph.D.
CURRICULUM VITAE

PERSONAL HISTORY:

University of California, Los Angeles
David Geffen School of Medicine
Department of Medicine
Division of Hematology/Oncology

EDUCATION:

B.A. (Biology)
1970
Washington & Jefferson College
Washington, Pennsylvania

Ph.D. (Cell Biology)
1974
Pritzker School Medicine
University of Chicago
Chicago, Illinois

M.D.
1975
Departments of Anatomy and Pathology
University of Chicago
Chicago, Illinois

Intern
1975-76
University of Chicago Hospitals and Clinics
Chicago, Illinois

Resident
1976-78
University of Chicago Hospitals and Clinics
Chicago, Illinois

Chief Resident
1978-79
University of Chicago
Chicago, Illinois

Fellow, Division of Hematology-Oncology
1979-82
UCLA School of Medicine, Los Angeles

LICENSURE:

California
April 2, 1979
G39056

DEA
February 19, 2009
AS8603509

BOARD CERTIFICATION:

Internal Medicine
September 13, 1978
Certificate No. 66443

Medical Oncology
November 10, 1981
Certificate No. 66443

PROFESSIONAL EXPERIENCE:

Present Academic Appointment

Professor of Medicine, A/S
David Geffen School of Medicine at UCLA
Department of Medicine
2012-present

Endowed Chair
The Bowyer Professorship of Medical Oncology
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
2001-present

Previous Academic Appointments

Adjunct Assistant Professor of Medicine
UCLA School of Medicine
Department of Medicine
1982-1984

Assistant Professor-in-Residence
UCLA School of Medicine
Department of Medicine
1984-1987

Associate Professor-in-Residence
UCLA School of Medicine
Department of Medicine
1987-1989

Associate Professor of Medicine
UCLA School of Medicine
Department of Medicine
1989-1993
Professor of Medicine
David Geffen School of Medicine at UCLA
Department of Medicine
1993-2012

Present Administrative Appointments

Director of Clinical and Translational Research
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
1988-Present

Chief
Division of Hematology-Oncology
UCLA School of Medicine
1992- Present

Executive Vice-Chair for Research
Department of Medicine
UCLA School of Medicine
1994-Present

Director
Search Committee
UCLA Revlon Breast Center
1996-Present

Director and Member of Executive Management Committee
Translational Research in Oncology (TRIO) [Formerly known as Cancer International Research Group (CIRG)]
2002-Present

Board of Directors
Translational Research in Oncology-United States (TRIO-US) [Formerly known as Translational Oncology Research International (TORI)]
UCLA Jonsson Comprehensive Cancer Center
2003-Present

Secretary
Translational Research in Oncology-United States (TRIO-US) [Formerly known as Translational Oncology Research International (TORI)]
UCLA Jonsson Comprehensive Cancer Center
2003-Present

President
Translational Research in Oncology-United States (TRIO-US) [Formerly known as Translational Oncology Research International (TORI)]
UCLA Jonsson Comprehensive Cancer Center
2005-Present

Board Member
Translational Research in Oncology (TRIO) [Formerly known as Cancer International Research Group (CIRG)]
2005–Present

Previous Administrative Appointments

Associate Chief
Division of Hematology-Oncology
Department of Medicine
UCLA School of Medicine
1989-1991

Vice-Chair for Finance
Department of Medicine
UCLA School of Medicine
1992-1994

Vice-Chair for Research
Department of Medicine
UCLA School of Medicine
1992-1994

Chair
Search Committee for Chair of the Department of Pediatrics
UCLA School of Medicine
1993-1994

Chief
Search Committee for Chief
Division of Pulmonary and Critical Care Medicine
Department of Medicine
UCLA School of Medicine
1998

PROFESSIONAL ACTIVITIES:

Committee Service:
American Association for Cancer Research
1990-Present

Directors Administration Review Committee
Committee member

Jonsson Comprehensive Cancer Center
1991-Present

Leadership Advisory Council (Committee member)
Jonsson Comprehensive Cancer Center
1991-Present

Director & Member
UCLA JCCC Women’s Cancers Program Area
1992-Present

Department of Medicine Executive Committee (Committee Member)
UCLA School of Medicine
1992-Present

Director’s Council (Council Member)
Jonsson Comprehensive Cancer Center
1992-Present

Breast Center Steering Committee
UCLA Medical Center
1992-Present

Dean’s Advisory Council
Jonsson Comprehensive Cancer Center
1993

Search Committee for Chair of the Department of Pediatrics
UCLA School of Medicine
1993-1994

STAR (Specialty Training Academic Research) Program
Department of Medicine
UCLA School of Medicine
1994-1996

Bowyer/Joint Oncology Center Steering Committee (Committee Member)
UCLA Medical Center
1994-Present

Internal Scientific Review Committee (Committee Member)
UCLA Medical Center
1994-Present

Integration Panel
U.S. Army Medical Research and Material Command
Breast Cancer Research Program
1994-Present

Search Committee
Dean-School of Dentistry
1995-1996

Master Planning I – Clinical and Applied Research Sub-Committee
1996

Blue Ribbon Committee for Procedures for the Protection of Human Subjects
UCLA
1996

Search Committee
Revlon Breast Center
1996-1997

Master Planning II- Programs and Partnerships Committee
1997

Search Committee for Chief
Division of Pulmonary and Critical Care Medicine
Department of Medicine
UCLA School of Medicine
1998

Member of the President’s Cancer Panel
2000-2003

American Society for Clinical Investigation
1988-Present

Community Service:

EIF Revlon Run/Walk for Women
1993-2014

Lee Jeans Denim Day
2006-2008

Par for the Cure
2007-2008, 2016

Professional Associations:

American Association for the Advancement of Science
1990-Present

American Association for Cancer Research
1990-Present

Scholarly Societies:

American Society for Clinical Investigation
1998-2008

American Society of Clinical Oncology
1998-Present

Editorial Services (Reviewer):
Current Opinion in Oncology
1992

The Journal of Nuclear Medicine
1992

Journal of the National Cancer Institute
2005-2008

Proceedings of the National Academy of Sciences
2008

Consulting Activities:

Scientific Advisory Board
ChromaVision
1999

Scientific Advisory Board
Sugen/Pharmacia
1999-2003

Member of the President’s Cancer Panel
2000-2003

Panel Member
National Institutes of Health, Washington D.C.
2002

National Breast Cancer Coalition, Washington D.C.
2005-2008

Scientific Advisory Board
Sanofi-Aventis International Breast Cancer Conference (IBCC)
2006-2014

Scientific Advisory Board
Campbell Family Institute for Breast Cancer Research
2011

Advisory Board
GlaxxoSmith Kline (GSK) Asia Pacific Japan Emerging Markets (APJEM) Presentation
2011

Advisory Board
Sanofi Oncology Breast Cancer
2011

Scientific Advisory Board
Amgen, Inc – AMG 386
2011

Scientific Advisory Board
Pfizer, Inc – CDK4/6 Inhibitor
2011-2015

Scientific Advisory Board
Novartis Oncology – LEAD Summit
2011-present

Advisory Board
HealthCare Pharmaceuticals – External Innovation Therapeutics Drug Review
2014

Board Member
Biomarin Pharmaceuticals
2014-present

Scientific Advisory Board
Lilly Abemaciclib Global
2015

Pipeline National Advisory Board
Boehringer Ingelheim
2016

Bayer Oncology Thought Leader Summit
Bayer Oncology
2016

Medici Advisory Board
EMD Serono
2017

HONORS AND SPECIAL AWARDS:

Phi Sigma Award in Biology
Washington & Jefferson College
Washington, Pennsylvania
1970

Upjohn Award in Internal Medicine
University of Chicago Hospitals and Clinics
Chicago, Illinois
1976

Triton Biosciences, Inc.
Research Directors Award for Outstanding Biomedical Research
Alameda, California
1986

Western Society of Clinical Investigation
Outstanding Young Investigator Award
Los Angeles, California
1988

Elected to American Society of Clinical Investigation (ASCI)
Ann Arbor, Michigan
1988

Milken Family Medical Foundation Award in Cancer Research
Santa Monica, California
1988

National Breast Cancer Coalition
1998 Special Recognition for Scientific Advances in Human Breast Cancer
Washington, DC
1998

Americans for Medical Progress Education Foundation
Albert B. Sabin Heroes of Science Award
Alexandria, West Virginia
1999

American Association of Cancer Research (AACR)
23rd Richard and Hinda Rosenthal Foundation Award
Philadelphia, Pennsylvania
1999

University of California, San Diego
Salk Translational Award
San Diego, California
2000

Bristol Myers Squibb Millennium Award
New York, New York
2000

Brown-Hazen Award for Excellence in the Basic Sciences
Wadsworth Center
Albany, New York
2001

Alumni Award
Washington & Jefferson College
Washington, Pennsylvania
2001

Jeffrey A. Gottlieb Memorial Award
M.D. Anderson Cancer Center
Houston, Texas
2002

American Association of Cancer Research (AACR)
2nd Annual Dorothy P. Landon Award for Translational Cancer Research
Philadelphia, Pennsylvania
2003

American Cancer Society
Medal of Honor for Clinical Research
Oklahoma City, Oklahoma
2004

Altman Cancer Center Research Award
Kent State University
Kent, Ohio
2005

Distinguished Service Award
Medical and Biological Sciences Alumni Association
University of Chicago
Chicago, Illinois
2005

William L. McGuire Memorial Award
San Antonio Breast Cancer Symposium
San Antonio, Texas
2005

18th Annual Donald Ware Waddell Award
Arizona Cancer Center
Tucson, Arizona
2006

American Society of Clinical Oncology
David A. Karnofsky Memorial Award
Oklahoma City, Oklahoma
2006

European Institute of Oncology Breast Cancer Award
Milan, Italy
2006

2nd Umberto Veronesi Award for the Future Fight Against Breast Cancer
Cancun, Mexico
2006

Lister Award for Translational Medicine
University of Glasgow
Glasgow, Scotland
2006

Friends of the National Library of Medicine
Distinguished Medical Service Award
Washington, DC
2007

The Gairdner Foundation International Award
Toronto, Canada
2007

Warren Alpert Foundation Award
Harvard Medical School
Boston, Massachusetts
2007

The Daniel Nathans’ Memorial Award
Van Andel Research Institute
Grand Rapids, Michigan
2008

UCLA Medical Alumni & Aesculapians Honoree
Medical Science Award
Los Angeles, California
2009

Scheele Award
Swedish Academy of Pharmaceutical Science
Stockholm, Sweden
2009

Medical Education Initiative on Molecular Targeted Therapy of Cancer (MTTC)
Life Achievement Award
2011

Royal College of Physicians of Ireland (RCPI)
Election as a fellow via distinction
2013

National Consortium of Breast Cancers (NCBC)
Impact Award
2013

American Association for Cancer Research (AACR)
Induction as a Fellow of the AACR Academy
2013

Hope Funds for Cancer Research
Award of Excellence
2013

Thomson Reuters – Scientific and Scholarly Research
Citation Laureate in Physiology or Medicine
2013

Board of Directors of the Pennsylvania Breast Cancer Coalition (PBCC)
Potamkin Prize
2013

OncLive
Giant of Cancer Care Inductee (Breast Cancer)
2014

University of Alberta
Honorary Doctor of Science Degree
2015

UC San Diego Moores Cancer Center
Duane Roth Award
2016

WVU Cancer Institute
Laurence & Jean Delynn Lecture
2016

Dalian University of Technology
Hua Tuo Prize
2016

Susan G. Komen®
Brinker Award for Scientific Distinction in Clinical Research
2017

New York Metropolitan Breast Cancer Group
Guy Robbins Award for Breast Cancer
2019

Royal Swedish Academy of Sciences
Sjöberg Prize
2019

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:
NIH
P01 CA32737
Title: Signal Transduction in Oncogenesis
Research
$410,031
04/01/82-06/30/07
Principal Investigator

American Cancer Society
Research
$205,000
1988-1993
Principal Investigator

NCI
NO1-CM-87289
Research
$1,182,000
07/01/89 – 09/29/93
Principal Investigator

NIH
NIDDKD DK07285
Title: Academic Training in Hematology
Training Grant
$490,900
07/01/89 – 06/30/94
Principal Investigator

NIH
NCI CA09297
Title: Academic Training in Medical Oncology
Training Grant
$539,800
07/01/89 – 12/31/94
Principal Investigator

NIH
NCI CA36827
Research
$1,174,384
07/01/89 -06/30/97
Principal Investigator

Revlon
Title: Revlon/UCLA Women’s Cancer Research Program
Research
$3,929,835
02/07/90 – indefinite
Director-Principal Investigator

UC Tobacco Related Disease
Research
$ 336,209
07/01/90 -06/30/93
Principal Investigator

NIH
NCI CA 32737
Title: Signal Transduction in Oncogenesis
Research
$1,818,564
12/01/91 – 11/30/94
Principal Investigator

Genentech
H0191G/H0193G
Clinical Trial
$40,000
04/01/91 – 07/30/92
Principal Investigator

Genentech
H0407G
Clinical Trial
$61,100
06/01/92 – 05/30/93
Principal Investigator

Genentech
H0453G
Clinical Trial
$100,000
10/01/92 – 09/30/93
Principal Investigator

Genentech
H0452G
Clinical Trial
$55,000
11/01/92 – 10/31/93
Principal Investigator

NIH
NCI CA58197
Developmental Funds
$493,877
09/30/92 – 09/29/95
Principal Investigator

NIH
RO1 CA36827
Title: Signal Transduction in Oncogenesis
Research
$827,715
7/1/92 – 6/30/97
Principal Investigator

NIH
NCI 017114-01
Inst. Career Development Program
$855,777
9/30/92 – 8/31/97
Principal Investigator

NIH
NCI CA01714
Inst. Career Development Program
$702,777
09/30/92 – 08/31/97
Principal Investigator

Genentech
H0552G
Clinical Trial
$87,875
03/93 -02/94
Principal Investigator

Amgen
Title: Program in Applied Basic
Research
$2,437,979
4/1/93 – 3/31/97
Principal Investigator

NIH
NIDDKD DK07285
Title: Academic Training in Hematology
Training Grant
$490,900
07/01/94 – 06/30/00
Principal Investigator

NIH
NCI CA09297
Title: Academic Training in Medical Oncology
Training Grant
$539,80
07/01/94 – 12/31/00
Principal Investigator

USAMRDC
Title: Breast Cancer Research Program
Research
$800,000
7/11/94 – 8/10/98
Principal Investigator

USAMRDC
Title: Breast Cancer Research Program
Research
$899,000
9/15/94 – 10/14/98
Principal Investigator

Genentech
H0648G, H0649G, H0650G
Clinical Trial
$204,200
3/1/95 -2/28/97
Principal Investigator

NIH
NCI P01 CA32737
Research
$4,515,779
08/29/95 -05/31/00
Principal Investigator

NCI CA16042-28
Cancer Center Support Grant–CCSG
2/1/97 – 11/30/02
Principal Investigator

Rhone-Poulenc Pharmaceuticals
#US11122
Title: Randomized, Phase II Trial of Taxotere (Docetacel), Carboplatin & Herceptin (TCH) in Treatment of Metastic Breast Cancer
Clinical Trial
$9,000/pt for 62 patients for a total study amount of $558,000
11/30/99 – 11/30/02
Principal Investigator

BioSTAR/Amgen
20010371
Title: Integration of Genomics-Based Technologies into a Streamlined Discovery Process for Antibody Therapeutics to Treat Human Cancers
Clinical Trial
$484,000.
1/12/01 – 1/11/02

NIH/National Cancer Institute CA090848 (Bilchik)
Title: Ultrastaging of Early Colon Cancer
Research
$223,571 (Total project direct $111,785)
04/01/01-07/31/12
Role: Collaborator

Agency: BCIRG
Award #: BCIRG 005
Tittle: Phase III Multicenter Randomized Breast Cancer Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) verses Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC>T) as Adjuvant Treatment of Operable Breast Cancer her2neu Negative Patients with Positive Axillary Lymph Nodes.
Role: PI
Percent Effort: 1%
Project period: 6/1/01-12/31/13
Level of funding: $1,066,299

Agency: BCIRG
Award#: BCIRG006
Tittle: Phase III A Multicenter Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC>T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC>TH) and with Docetaxel, Platinum Salt and Trasuzumab (TCH) in the Adjuvant Treatment of Node Positive and High Risk Node Negative Patients with Operable Breast Cancer Containing the HER2neu Alteration.
Role: PI
Percent effort: 1%
Project period: 06/01/01-12/31/14
Level of funding: $2,177,946

NIH
T32 CA09297: 21
Title: Academic Training in Medical Oncology
Training Grant
$1,254,094
8/1/01 – 6/30/06
Principal Investigator

NIH
CA 32737:18A2
Title: Signal Transduction in Oncogenesis
Research
$5,765,341
09/16/02 – 06/30/08
Principal Investigator

NIH/National Cancer Institute
CA016042 (Gasson)
$57,825
4/23/2003-11/30/2013
Principal Investigator

American Cancer Society
CRP-04-233-01
Clinical Research Professorship
$300,000
07/01/04 – 06/30/10
Principal Investigator

Charles R, Drew University of Medicine & Science
2007-JV-D22830
Title: Drew-UCLA Breast Cancer Research and Training Partnership; Molecular/Cellular Pathogenesis Model
Research & Training
$170,249
03/01/05 – 02/28/08
Principal Investigator

Department of Defense
W81-XWH-05-10395
Title: An Integrated Program in Translational Research in Human Breast Cancer
Research
$ 5,012,445
05/16/05 -6/15/10
Principal Investigator

Agency: Novartis
Award #: 20062112:04
Complete Title: A preclinical research program to evaluate potential translational science for the histone deacetylase (HDAC) inhibitor LBH589
Role: PI
Effort: 1%
Amount: $1,955,836
Project Dates: 07/01/2006 – 8/31/2012

NIH/National Cancer Institute
U54 CA143930-01 (Koeffler)
Title: Charles Drew University/UCLA Center Partnership to Eliminate Cancer health Disparities
Research
$ 50,205 (Annual direct $16,735)
09/29/2009 – 08/31/2012
Principal Investigator

Agency: AACR
Award #:SU2CAACRDT0409
Complete Title: An integrated Approach to Targeting Molecular Breast Cancer Subtypes and Their Resistance Phenotypes
Role: PI
Effort: 10%
Amount: $15,000,000 (Annual direct $3,000,000)
Project Dates: 10/01/2009-09/30/2014

CIRM (Disease Team Awards)
DR1-01477 (Slamon)
Title: Therapeutic Opportunities to Target Tumor Initiating Cells in Solid Tumors
Research
Percent effort: 30%
$ 3,879,151 (Annual direct $4,994,915)
05/01/2010-04/30/2014
Principal Investigator

Agency: ONYX Pharmaceuticals
Award #: 20103658
Tittle: A preclinical research program to evaluate potential translational science for the ONYX development molecules: carfilzomib, ONX 0912, ONX 0801.
Role: PI
Percent effort: 1%
Project period: 10/1/10-9/30/12
Level of funding: $317,885

Agency: DOD US Army
Award #: W81XWH-11-1-0104
Complete Title: An Integrated Program in Translational Research in Human Breast Cancer
Role: PI
Effort: 20%
Amount: $1,000,000
Project Dates 03/01/2011- 03/31/2016

Agency: Eli Lilly
Award #: 20112001
Complete Title: Preclinical evaluation of Eli Lilly’s CDK4/6 small molecule inhibitor abemaciclib in UCLA/TORL’s cell line xenograft models of human breast cancer.
Role: PI
Effort: 1%
Amount: 178,846
Project Dates 11/29/2011-09/30/2016

Agency: Genentech
Award #: OAM4861g
Tittle: A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MetMAB and/or Bevacizumab in Combination with Paclitaxel in Patients with Metastatic, Triple-Negative Breast Cancer.
Role: PI
Percent Effort: 1%
Project period: 12/01/11-02/28/15
Level of funding: 192,211

Agency: Bayer
Award#: PO#2110499253
Tittle: A Preclinical Research Program to Evaluate Potential Translational Science for the Bayer CDK Inhibitor BAY 1000394 and the PI3 Kinase Inhibitor BAY 80-6946, Allo-AKT Inhibitor BAY 1125976 and FGFR Inhibitor BAY 1163877.
Role: PI
Percent effort: 1%
Project period: 11/1/13-12/31/14
Level of funding: $190,535

Agency: Pfizer
Award#: A5481023
Tittle: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (Faslodex®) With or Without PD-0332991 (Palbociclib) ± Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy.
Role: PI
Percent Effort: 1%
Project Period: 11/26/13-11/26/17
Level of funding: $345,811

Agency: CIRM
Award #: DR3-07067
Complete Title: A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors
Role: PI
Effort: 30%
Amount: $ 1,506,802
Project Dates 05/01/2014-4/30/2017

Agency: AACR
Award #: 20143716
Complete Title: Clinical Development of CFI-400945, a PLK4 Inhibitor, in Breast Cancer
Role: PI
Effort: 18%
Amount: $125,000
Project Dates 06/01/2014-05/30/2016

Agency: NIH Via Stanford University
Award #: R01 CA182514-01A1
Complete Title: Intergrated genomic analysis and multi-scale modeling of therapeutic resistance
Role: Co-PI PI: Curtis
Effort: 2%
Amount: $13,526
Project Dates: 09/12/2014-08/31/2019

Agency: US Army Via John Hopkins University
Award #: W81XWH-14-1-0385
Complete Title: A New Paradigm for the treatment of Ovarian Cancer: The use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy.
Role: Collaborator PI: Baylin
Effort: 5%
Amount: $62,856
Project Dates: 09/30/2014-09/29/2019

Agency: Zymeworks
Award #: 20151771
Complete Title: Antibody Drugs Conjugate (ADC) Efficacy in Translational Oncology Research Laboratory (TORL) Breast Cancer Cell Panel
Role Co-PI (PI: Hurvitz)
Effort: 1%
Amount: $41,500
Project Dates: 10/22/2014-10/21/2015

Agency: NIH/NCI
Award #:P30 CA016042
Complete Title: “Cancer Support Grant”
Role: Collaborator PI: Gasson
Effort: 18%
Amount: $145,709
Project Dates: 12/01/2014-11/30/2015

Agency: Novartis
Award #: CLEE011F2301
Tittle: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment.
Role: PI
Percent effort: 1%
Project Period: Pending
Level of funding: Pending

LECTURES AND PRESENTATIONS:

Designing a Smart Clinical Trials System for the 21st Century
“Optimizing the Interactions between Basic and Clinical Science”
Leesburg, Virginia
September 9-11, 2004

4th Annual California Cancer Consortium Conference
“Recent Advances and New Directions in Cancer Therapy”
Yountville/Napa Valley, California
March 11-13, 2005

National Cancer Institute, National Human Genome Research Institute, and National Institutes of Health
Toward a Comprehensive Genomic Analysis of Cancer: A Roundtable Discussion
Washington, DC
July 20-22, 2005

Florida Hospital Cancer Institute
“Breast Cancer—Evolution of Targeted Therapy”
Orlando, Florida
October 20, 2005

The University of Chicago
“Chromosomes and Cancer: From Translocations to Targeted Therapies” (In honor of Janet Davison Rowley’s 80th Birthday Celebration)
Chicago, Illinois
November 6-7, 2005

National Breast Cancer Coalition Fund
NBCC Consensus Conference
“Shaping the Future of Biomarker Research in Breast Cancer to Ensure Clinical Relevance”
Philadelphia, Pennsylvania
November 13-15, 2005

AACR 2006 Drugging the Cancer Genome Meeting
“Developing Rational Combination Therapies for Multigene Cancers”
Rancho Mirage, California
January 26-29, 2006

Keystone Symposia on Molecular and Cellular Biology
“Cancer and Kinases: Lessons from the Clinic”
Santa Fe, New Mexico
February 14-19, 2006

ASCO-ESMO-PSCO
First International Educational Conference
“From the Laboratory to Clinical Practice Current Perspectives in Oncology”
Warsaw, Poland
May 9-12, 2006

International Society for Biological Therapy of Cancer 21st Annual Meeting
“Primer on Tumor Immunology and Biological Therapy”
October 26, 2006

Sanofi-Aventis
1st International Breast Cancer Conference (IBCC)
“Breast Cancer Management in 2007—Opportunities and Challenges:
Paris, France
February 4-5, 2007

GlaxoSmithKline
7th Annual Canadian Oncology Winter Conference (COWC)
Targeted Therapy and Chemotherapy in Oncology
“Participate in Case-Based Breakout Session”
Sun Peaks, British Columbia
March 3, 2007

GlaxoSmithKline
7th Annual Canadian Oncology Winter Conference (COWC)
“Beyond Herceptin: Molecular Targeted Therapy for Breast Cancer”
Sun Peaks, British Columbia
March 3, 2007

Sanofi-Aventis Advisory Board
“VEGF-Trap Development in Breast Cancer”
New York, New York
March 6, 2007

Sanofi
“Early Breast Cancer”
St. Gallen, Switzerland
March 12, 2007

Sanofi- Aventis
“Introduction to TOP2A and the Clinical Setting”
St. Gallen, Switzerland
March 15, 2007

CBCE
“Combinations as Adjuvant Therapy in HER2+ Disease”
Philadelphia, Pennsylvania
April 14, 2007

AACR
“Molecular Characterization of Human Breast Cancer: Diagnostic and Therapeutic Implications”
Los Angeles, California
April 16, 2007

Gairdner Foundation
2007 International Awards Ceremony
“The Diversity of Human Breast Cancer”
Toronto, Canada
April 18, 2007

Sanofi-Aventis
“BCIRG Trials in Breast Cancer”
Cancun, Mexico
April 21, 2007

Vanderbilt – Ingram Cancer Center Retreat
“Updated on HER -2 Directed Therapy”
Nashville, Tennessee
May 4, 2007

Genentech
“HER2 Targeting Agents in Clinical Practice Improving Patient Outcomes from Early to Advanced Breast Cancer”
Washington D.C.
May 7, 2007

Genentech
“HER2 Targeting Agents in Clinical Practice Improving Patient Outcome from Early to Advanced Breast Cancer”
Bethesda, Maryland
May 8, 2007

Genentech
“HER2 Targeting Agents in Clinical Practice Improving Patient Outcome from Early to Advanced Breast Cancer”
Rockville, Maryland
May 8, 2007

Mayo Clinic
“Molecular Diversities of Human Breast and Ovarian Cancers and their Therapeutic Implications”
Rochester, Minnesota
May 24, 2007

2007 Annual Meeting American Society of Clinical Oncology (ASCO)
“Charting Rough Water: How Do We Navigate from Target to Therapy?”
Chicago, Illinois
June 2, 2007

Roche
‘Historical Perspective to Herceptin in context with all settlings it is used – to focus on adjuvant setting”
Salvador, Bahia, Brazil
June 16, 2007

University Health Network
Keynote Address “Clinical Perspectives II”
Toronto, Canada
July 31, 2007

Amgen Oncology
“Current and Future Directions in Breast Cancer Therapy”
Washington D.C.
August 4, 2007

GlaxoSmithKline
“A Look at the Future – Breast Cancer from 2010 to 2020”
Sydney, Australia
August 25, 2007

GlaxoSmithKline
“The Challenge of ErbB Receptor Inhibition”
Sydney, Australia
August 25, 2007

Western General Hospital – Controversies in Breast Cancer
“Choice of Chemotherapy”
Edinburgh, Scotland
September 3, 2007

Clinical Investigator ‘Think Tank”
“Choice of chemotherapy regimen in adjuvant therapy for patients with HER2 – negative Disease-Agree, Disagree in between?”
San Francisco, California
September 8, 2007

National Institute For Cellular Biotechnology
“HER-2/Neu as a Therapeutic Target”
Glasnevin, Ireland
September 8, 2007

Pfizer Oncology
“From Clinical Trial to Clinical Practice Looking for Patient Benefits”
Rome, Italy
September 14, 2007

14th European Cancer Conference (ECCO)
“Emerging Role of Anti-angiogenic Tyrosine Kinase Inhibitors n Breast Cancer”
Barcelona, Spain
September 23, 2007

14th European Cancer Conference (ECCO)
“What’s Next for the BCIRG?”
Barcelona, Spain
September 26, 2007

14TH EUROPEAN CANCER CONFERENCE (ECCO)
“Optimizing Treatment of HER2-positive Breast Cancer with Docetaxel non/anthracycline Regimens – BCIRG006”
Barcelona, Spain
September 26, 2007

Florida Hospital Cancer Institute
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Orlando, Florida
October 4, 2007

Florida Hospital Cancer Institute
“Applying Targeted Therapy in Breast Oncology”
Orlando, Florida
October 4, 2007

Capri Science Conference
“Cancer Therapeutics: The Road Ahead”
Capri, Italy
October 8-10, 2007

Capri Science Conference
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Capri, Italy
October 10, 2007

Sixth International Symposium On Traslational Research In Oncology
“Growth Factors and Growth Factor Receptors
Dublin, Ireland
October 12, 2007

Gairdner Foundation
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Edmonton, Canada
October 22, 2007

Gairdner Foundation
“The Diversity of Human Breast Cancer”
Edmonton, Canada
October 22, 2007

Gairdner Foundation
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Toronto, Canada
October 23, 2007

Gairdner Foundation
“The Diversity of Human Breast Cancer”
Toronto, Canada
October 26, 2007

NCI/FDA
“History of HER-2 and Development of Herceptin”
Bethesda, Maryland
October 29, 2007

Daniel Den Hoed Symposium
“History, Mechanism of Action and Clinical Application of Herceptin”
Rotterdam, The Netherlands
November 29, 2007

Daniel Den Hoed Symposium
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Rotterdam, The Netherlands
November 30, 2007

30th Annual San Antonio Breast Cancer Symposium (SABCS)
“Herceptin (Trastuzumab) for the Adjuvant Treatment of HER2-Positive – Node-Positive Breast Cancer”
San Antonio, Texas
December 10, 2007

30th Annual San Antonio Breast Cancer Symposium (SABCS)
“Herceptin (Trastuzumab) for the Adjuvant Treatment of HER2-Positive – Node-Positive Breast Cancer”
San Antonio, Texas
December 11, 2007

30th Annual San Antonio Breast Cancer Symposium (SABCS)
“Combination on Approach to Targeting Multiple Pathways: Preliminary Clinical Results”
San Antonio, Texas
December 12, 2007

30th Annual San Antonio Breast Cancer Symposium
“Role of Anthracycline-based Therapy in the Adjuvant Treatment of Breast Cancer: Efficacy Analyses Determined by Molecular Subtypes of the Disease”
San Antonio, Texas
December 13, 2007

30th Annual San Antonio Breast Cancer Symposium
“Antibodies and Immunotherapy”
San Antonio, Texas
December 14, 2007

30th Annual San Antonio Breast Cancer Symposium (SABCS)
SABCS Satllite
“Early-Stage HER2-Overexpressing Breast Cancer: Maximizing Safety and Efficacy through Appropriate Patient Selection”
December 14, 2007

30th Annual San Antonio Breast Cancer Symposium
“Topo IIa, HER2, and Anthracycline Sensitivity in Breast Cancers: Rational Therapeutic Implications”
San Antonio, Texas
December 15, 2007

Oncology Learning Center
“Point-Counter-Pointer”
Miami, Florida
January 20, 2008

Oncology Learning Center
“Clinical Applications of Personalized Therapies for HER2+ Breast Cancer”
Miami, Florida
January 20, 2008

Fifth Annual North American Symposium on Personalized Therapies for Breast Cancer
“Which Therapies Should be used for Trastuzumab Failures?”
Miami, Florida
January 20, 2008

2nd International Breast Cancer Conference (Sanofi-Aventis)
“Breast Cancer Management in 2008—Opportunities and Challenges”
Paris, France
February 3-4, 2008

NCRI
Cridian Lecture
“HERR2 in Breast Cancer: A Continuing Story”
London, England
March 6, 2008

NCI
“HER2/neu: Lessons Learned from Paired Diagnostics and Therapeutics”
Washington D.C.
March 13, 2008

CBCE
“HER2+ Disease: What’s New in Testing?”
Philadelphia, Pennsylvania
April 4, 2008

Eighth Annual New Strategies in Breast Cancer Conference
“Adjuvant Therapy of Breast Cancer – HER2+ Disease: What’s New in Testing?”
Philadelphia, Pennsylvania
April 5, 2008

99th Annual Meeting American Association for Cancer Research (AACR)
“Clinical Trials for Personalized Medicine – A Dream or a Dream Comes True?”
San Diego, California
April 12, 2008

99th Annual Meeting American Association for Cancer Research (AACR)
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
San Diego, California
April 13, 2008

99th Annual Meeting American Association for Cancer Research (AACR)
“New Concepts in Organ-Site Research Session on Topic “Breast Cancer”
San Diego, California
April 15, 2008

Sanofi-Aventis
“Further Individualization of EBC Treatment: Integrating Science and Clinical Practice”
Berlin, Germany
April 16, 2008

GlaxoSmithKline
“Achieving Cure: New Advances in Curative Setting”
Seoul, South Korea
April 19, 2008

GlaxoSmithKline
“Optimizing Patient Treatment after Progression on Trastuzumab”
Seoul, South Korea
April 19, 2008

Society for Integrative Oncology
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Shanghai, China
April 25, 2008

Roche
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Cardiff, Wales
April 30, 2008

The Royal Society – Breast Cancer Campaign Scientific Conference
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
London, England
May 12, 2008

Sanofi-Aventis
“TOPO IIA, HER2 and Anthracycline Sensitivity in Breast Cancers- Rational Therapeutic Indications”
Cape Town, South Africa
May 25, 2008

Genentech
“Results of the BCIRG 006 Trial”
Chicago, Illinois
May 29, 2008

Sanofi-Aventis
“BCIRG006 study results and implications on the adjuvant treatment of HER2-positive breast cancer”
Chicago, Illinois
May 30, 2008

ASCO
“Randomized study of Pazonanib +Lapatinib alone in patients with HERS2 positive advanced or metastatic breast cancer [Phase II]”
Chicago Illinois
June 1, 2008

American Society of Clinical Oncologists (ASCO)
“Randomized Study of Pazopanib + Lapatinib vs. Lapatinib Alone in Patients with HER-2 Positive Advanced or Metastatic Breast Cancer”
Chicago, Illinois
June 1, 2008

3rd Interamerican Conference
“Targeted Therapies: Clinical Data Update and Emerging Agents and Regimens”
Cancun, Mexico
July 24, 2008

Department of Defense
“The Use of Anthracyclines”
Baltimore, Maryland
June 26, 2008

GlaxoSmithKline
“Targeted Therapy in Oncology” plus 15-minute discussion
“Suggestion: 20 Years HER-2 neu Receptor”
Munich, Germany
July 8, 2008

IABCC
“HER Family Marker Trials Update”
Cancun, Mexico
July 24, 2008

Florida Hospital Cancer Institute
Annual National Advisory Board Meeting
“Applying Targeted Therapy in Breast Oncology”
Orlando, Florida
October 2, 2008

7th International Symposium on Translational Research In Oncology
Clinical Care Option Oncology
“Session I: Growth Factors and Growth Factors Receptors”
Huntington Beach, California
October 17, 2008

7th International Symposium on Translational Research in Oncology
Clinical Care Option Oncology
“Pazopanib, a VEGF Inhibitor”
Huntington Beach, California
October 18, 2008

10th Annual Lynn Sage Breast Cancer Symposium
“Rethinking Chemotherapy in the HER-2+ Patient”
Chicago, Illinois
October 24, 2008

10th Annual Lynn Sage Breast Cancer Symposium
Northwestern University
“Rethinking Chemotherapy in the HER2+ Patient”
Chicago, Illinois
October 25, 2008

Accademia Nazionale di Medicina
Advanced Course on Breast Cancer
HER2+ Tumors: Schedule and Druation of anti-HER2 Treatment
Modena, Italy
November 6, 2008

GlaxoSmithKline
“Optimizing Patient Treatment after Progression on Trastuzumab”
Dubai, United Arab Emirates
November 14, 2008

GlaxoSmithKline
“Achieving Cure: New Advances in Curative Settings”
Dubai, United Arab Emirates
November 14, 2008

GlaxoSmithKline
“Controversies in Breast Cancer”
Montevideo, Uruguay
November 20, 2008

GlaxoSmithKline
“Who Benefits from Anthracyclines in the Adjuvant Setting in Breast Cancer?”
Montevideo, Uruguay
November 21, 2008

GlaxoSmithKline
“New Perspectives in Targeted Therapies in Breast Cancer”
Montevideo, Uruguay
November 21, 2008

GlaxoSmithKline
“Understanding and Treating Basal Breast Cancer (Triple Negative Disease)”
Montevideo, Uruguay
November 21, 2008

The Daniel Nathan’s Memorial Award Van Ander Research Institute
“The Diversity of Human Breast Cancer”
Grand Rapids, Michigan
December 8, 2008

The Daniel Nathan’s Memorial Award Van Ander Research Institute
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Grand Rapids, Michigan
December 9, 2008

31st Annual San Antonio Breast Cancer Symposium
“Anthracyclines in Early Breast Cancer: Patient Perspectives and Expert Debate”
San Antonio, Texas
December 10-14, 2008

The Campbell Family Institute for Breast Cancer Research and Ontario Cancer Institute
Weekend to End Breast Cancer Symposium
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Ontario, Canada
March 6, 2009

CBCE -9th Annual New Strategies in Breast Cancer Conference
“HER2-Overexpressing Disease: What’s New in Testing?”
Philadelphia, Pennsylvania
April 4, 2009

AIMGroup – Regina Elena National Cancer Institute
“Molecular Basis of Targeted Therapies”
Rome, Italy
April 17, 2009

10th Annual Meeting of The American Society of Breast Surgeons
“HER-2 Neu Therapy”
April 24, 2009
San Diego, California

Gairder/ Alberta Cancer Research Institute (ACRI)
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Alberta, Canada
May 21, 2009

Sanofi-Aventis
“HER2 Post-Progression”
London, England
June 17, 2009
NIH/NCI National Cancer Institute
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Bethesda, Maryland
June 22, 2009

Roche
“Targeting Excellence in HER2+ Breast Cancer Management”
London, England
July 1, 2009

ANZBCTG –ANZ Breast Cancer Trials Group
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Darwin, Australia
July 17, 2009

ANZBCTG – ANZ Breast Cancer Trials Group
“The Diversity of Human Breast Cancer “
Darwin, Australia
July 18, 2009

Sanofi-Aventis Symposium
“State of the Art in BF Including the Clinical Data and Benefits of Taxotere in Breast Cancer”
Vera Cruz, Mexico
August 28, 2009

Roche
“Anti-HER2 Therapy from Birth to the Next Decade”
Chalkidiki, Greece
September 5, 2009

AstraZeneca
“Controversies in Breast Cancer: Lessons for the Future”
Edinburgh, Scotland
September 8, 2009

Los Robles Hospital and Medical Center
Breast Cancer Treatment: The Role of Anthracyclines
Thousand Oaks, California
October 1, 2009

LA – Los Angeles Times Magazine Event
“Herceptin’s Future”
Rancho Palo Verdes, California
October 10, 2009

Annual National Advisory Board Meeting
“Applying Targeted Therapy in Breast Oncology”
Orlando, Florida
October 22, 2009

Florida Hospital Cancer Institute
“Update on Breast Cancer Therapy”
October 22, 2009
Orlando, Florida

Gairder – Ontario Institute Of Cancer Research
“Cancer: Can New Insights into Biology Yield Better Results?”
Ontario, Canada
October 30, 2009

Scheele Symposium
“Alterations of the HER2 Gene in Human Breast Cancer: Biologic and Therapeutic Implications”
Stockholm, Sweden
November 11, 2009

32nd San Antonio Breast Cancer Synposium (SABCS)
“Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (ACT) with Doxorubicin and Cyclophophamide Followed by Docetaxel and Trastuzumab (ACTH) with Docetazel, Carboplatin and Trastuzumab (TCH) in Her2/neu Positive Early Breast Cancer Patients: BCIRG 006 Study”
San Antonio, Texas
December 12, 2009

GlaxxoSmith Kline (GSK) Asia Pacific Japan Emerging Markets (APJEM) Presentation
“Role of Lapatinib in treatment of HER2+ MBC”
Riyadh, Saudi Arabia
January 13, 2010

German National Cancer Meeting
“Targeted Therapy of Breast Cancer: Current Status and Future Strategies”
Berlin, Germany
February 26, 2010

Oncology Learning Center
“HER2-Positive Diseases – Personalizing Therapies with Best Clinical Practices”
Torrey Pines, California
February 6, 2010

GlaxoSmithKline
“Update on Targeted Therapy for ErbB2+ Breast Cancer”
Dubai, United Arab Emirates
March 6, 2010

GlaxoSmithKline
“Optimization of Treatment for ErbB2 Positive Breast Cancer”
Santiago, Chile
April 29, 2010

GlaxoSmithKline
“Triple Negative Metastatic Patient: How Do We Proceed after Antracyclines and Taxanes?”
Santiago, Chile
April 29. 2010

GlaxoSmithKline
“Tykerb Efficacy in Combination with Capecitabine after First Progression to Trastuzumab”
Santiago, Chile
April 30, 2010

GlaxoSmithKline
“The Role of HER-2 Inhibitors in the Metastatic Setting”
Santiago, Chile
April 30, 2010

GlaxoSmithKline
“Is There Still a Role for Adjuvant Chemotherapy in Postmenopausal Patients?”
Santiago, Chile
April 30, 2010

GlaxoSmithKline
“Update of anti-HER2 Target Therapy for Breast Cancer”
Chicago, Illinois
June 6, 2010

The British Association for Cancer Research
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Edinburgh, Scotland
June 13, 2010

GlaxoSmithKline
“New Treatment Options in Patients with ErbB2 Positive Metastatic Breast Cancer”
Cancun, Mexico
July 6, 2010

GlaxoSmithKline
“Developing New Models of Investigation in Latin America CIRG-TRIO Experience”
Cancun, Mexico
July 7, 2010

GlaxoSmithKline
“Improving Survival Through Diagnostics and Pathology: Welcome and Introduction”
Cancun, Mexico
July 9, 2010

GlaxoSmithKline
“My Clinical Experience in Managing HER2+ve Metastatic Breasts Cancer Patients”
Wanchai, Hong Kong
July 29, 2010

Comprehensive Cancer Centers of Nevada
“On Discovery: Molecularly Targeted Therapy Pioneer to Speak”
Las Vegas, Nevada
September 28, 2010

GlaxoSmithKline
“A Focus on the Metastatic Setting of ErbB2+ Breast Cancer”
Istanbul, Turkey
October 1, 2010

GlaxoSmithKline
The New Expectations in ErbB2+ Breast Cancer
Istanbul, Turkey
October 1, 2010

ASCO-NCI-EORTC
“Lessons Learned from Clinical Utilization”
Ft. Lauderdale, Florida
October 19, 2010

UCLA Division Of Hematology Oncology & American Russian Medical Association
“Advances in Oncology in the 21st Century”
October 27, 2010
Beverly Hills, CA 90210

Hungarian Medical Oncology Society
“Modern Treatment of Breast Cancer”
Budapest, Hungary
November 12, 2010

Florida Hospital Cancer Center
“Lessons Learned from Clinical Utilization of Biomarkers in Breast Cancer”
Orlando, Florida
December 2, 2010

Fourth Annual Symposium on Personalized Therapies of Breast Cancer: Cased-Based Learning
“The new dilemma: targeting VEGF and/or the VEGFR receptor axis? What is the precise role of bevacizumab and multi-kinase inhibitors?”
La Jolla, California
January 22, 2011

American Association for Cancer Research 102nd Annual Meeting
“Molecular Diversity in Human Breast Cancer: Biologic and Therapeutic Implications”
Orlando, Florida
March 24, 2011

Warsaw Breast Cancer Congress – Diagnosis and Treatment of Breast Cancer
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Warsaw, Poland
April 15, 2011

GlaxxoSmith Kline (GSK) Asia Pacific Japan Emerging Markets (APJEM) Presentation
“Molecular Diversity in Human Breast Cancer: Biologic and Therapeutic Implications”
Antalya, Turkey
April 21, 2011

Cancer Clinics of Excellence Clinical Summit
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Ft. Lauderdale, Florida
April 29, 2011

Medical Education Initiative on Molecular Targeted Therapy of Cancer (MTTC)
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Rome, Italy
May 4, 2011

Clinical Care Options – ASCO TRIO Satellite
“Hot Topics in Translational Research: Transforming Cutting-Edge Discoveries to Clinical Practice”
Chicago, Illinois
June 5, 2011

2nd Annual- American Society of Clinical Oncology (ASCO) Update Conference
“ASCO Update on Breast Cancer”
Orlando, Florida
June 26, 2011

Korean Association for Clinical Oncology (KACO)/Korean Cancer Study Group (KCSG)
“HER2 Directed Therapy in Breast Cancer”
Seoul, Korea
August 27, 2011

2011 UCLA/TORI Lake Arrowhead Conference
“Translational Research in Molecular Oncology: Pathways vs. Histology”
Lake Arrowhead, California
October 8, 2011

Huntsman Cancer Institute and annual Molecular Cancer Research Training Program retreat
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Salt Lake City, Utah
November 3, 2011

CCCN 2nd Annual Keynote Event – On Research & Discovery
“Updates in Breast Cancer Research”
Las Vegas, Nevada
November 9, 2011

Roche Products (India) Pvt. Ltd. Special Symposia
“HER2 Positive Breast Cancer – Present and Future Perspectives”
Hotel Taj West End, Bangalore, India
January 17, 2012

Roche Products (India) Pvt. Ltd. Special Symposia
“HER2 Positive Breast Cancer – Present and Future Perspectives”
Hotel Taj Lands End, Mumbai, India
January 18, 2012

Roche Products (India) Pvt. Ltd. Special Symposia
“HER2 Positive Breast Cancer – Present and Future Perspectives”
Hotel ITC Sonar, Kolkata (Calcutta), India
January 19, 2012

Roche Products (India) Pvt. Ltd. Special Symposia
“HER2 Positive Breast Cancer – Present and Future Perspectives”
Hotel Taj Club House, Chennai, India
January 21, 2012

Roche Products (India) Pvt. Ltd. Special Symposia
“HER2 Positive Breast Cancer – Present and Future Perspectives”
Hotel Taj Mansingh, New Delhi, India
January 22, 2012

Fifth Annual Symposium on Personalized Therapies and Best Practices of Breast Cancer
“Personalized therapy for breast cancer 2012, including an update on
adjuvant therapy”
Tampa, Florida
February 25, 2012

AACR 2012 Annual Meeting Special Session – Stand Up To Cancer
“Maximizing Innovation Through Translational Research and Team Science: CDK4/6 Data Presentation”
Chicago, Illinois
April 1, 2012

Columbus Regional John B. Amos Cancer Center Lectureship Series
“Molecular Diversity in Human Breast Cancer”
The RiverMill Event Centre, Columbus, GA
May 3, 2012

Roche/Ebn Sina Medical (Agent of F. Hoffmann-La Roche Ltr) Speaker Series
“Update in the Management of HER-2 Positive Breast Cancer Patients”
Sheraton Doha, Doha, Qatar
May 15, 2012

UCLA/TRIO-US Annual Conference
“The TRIO Translational Research Model”
Lake Arrowhead, California
September 8, 2012

2012 Novartis ESMO Breast Cancer Symposium
“Developments in Targeted Strategies in HER2+ Breast Cancer”
Vienna, Austria
September 28, 2012

The 50th Annual Meeting of the Japan Society of Clinical Oncology c/o Congress Corporation
“Biologic and therapeutic implication of targeted therapy in breast cancer”
Yokohama Pacifico, Yokohama, Japan
October 27, 2012

Hoffmann- La Roche ltd. (Dubai Branch)/Tawam Hospital Emirates Oncology Conference
“HER-2 Positive Breast Cancer Session”
Emirates Palace, Abu Dhabi, UAE
November 9, 2012

Clinical Care Options, LLC HER2 Symposium at SABCS
“HER-2 Positive Breast Cancer: Applying the Latest Development to Clinical Practice”
Marriott Rivercenter, San Antonio, TX
December 6, 2012

UCLA Grand Rounds Lectureship Series
“The Diversity of Human Breast Cancer”
Tamkin Auditorium, UCLA, Los Angeles, CA
January 9, 2013

Irish Association for Cancer Research (IACR) Breast Symposium
“Personalized Therapies for Breast Cancer”
The Plaza Hotel, Dublin, Ireland
February 27, 2013

American Association for Cancer Research (AACR) Annual Meeting’s SU2C Sessions
“An integrated approach to targeting breast cancer molecular subtypes and their ‘resistance’ phenotypes”
Walter E. Washington Convention Center, Washington, DC
April 8, 2013

St. Mary’s Hospital & Medical Center 23rd Saccomanno Research Institute Lecture Series
“Molecular Diversity in Human Breast Cancer”
Spring Hill Suites, Grand Junction, CO
April 12, 2013

National Breast Cancer Coalition’s Inaugural Breast Cancer Deadline 2020 Advocate Leadership Summit
“The World of Breast Cancer in 2013: Where Are We Now?”
Crystal City Hyatt, Arlington, VA
May 5, 2013

2013 California Breast Cancer Research Program (CBCRP) Symposium
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Hilton Orange County/Costa Mesa, Costa Mesa, CA
May 18, 2013

2013 International Sentinel Node Society/Joint International Oncology Congress meeting
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Hilton San Francisco Financial District, San Francisco, CA
May 29, 2013

Pfizer JACK (Asia -Australia – Canada) Scientific Forum Speaker Series at ASCO 2013
“Evolution of Targeted Therapies in Breast Cancer: From Herceptin to Palbociclib”
Chicago Fairmont Hotel, Chicago, IL
June 1, 2013

UCLA Health Special Community Forums 2013
“Demystifying Cancer: Overcoming Challenges and Winning the War”
Ronald Reagan Presidential Library, Simi Valley, CA
October 30, 2013

UCLA Health Special Community Forums 2013
“Demystifying Cancer: Overcoming Challenges and Winning the War”
California Lutheran University, Lundring Events Center, Thousand Oaks, CA
November 7, 2013

The Breast Cancer Society of Taiwan
“From Bench to Bedside: From the Discovery of HER2 and the Rational Development of Trastuzumab to Current and Upcoming Approaches in the Adjuvant and Neoadjuvant Settings”
Sherwood Taipei Hotel, Taipei, Taiwan
September 14, 2013

UCLA/TRIO-US Lake Arrowhead Annual Conference
“TRIO Translational Research Model”
Lake Arrowhead, California
November 2, 2013

NBCC Project LEAD Advanced Topics at SABCS
“Clinical Trials Updates”
San Antonio, Texas
December 10, 2013

American Association for Cancer Research (AACR) Annual Meeting
“Pfizer CDK Oral Presentation”
San Diego, CA
April 6, 2014

Regional health 2014 Research in Compliance
“Keynote Speaking engagement to the 3rd Research in Compliance Conference”
Rushmore Plaza Holiday Inn, Rapid City, SD
April 29, 2014

Teva Oncology Symposium at ASCO
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Chicago, Illinois
May 31, 2014

UCLA Hematology/Oncology Special Fellowship Lecture
“Development of HER2/Neu directed therapies for Breast Cancer”
Los Angeles, California
August 26, 2014

UCLA Hematology/Oncology Special Fellowship Lecture
“Development of HER2/Neu directed therapies for Breast Cancer”
Los Angeles, California
September 4, 2014

UCLA/TRIO-US Annual Conference
“The TRIO Translational Research Model”
Lake Arrowhead, California
September 21, 2014

American Cancer Society San Francisco Soirée Honoree
“An Evening of Inspiration – The History of HER2”
San Francisco, California
October 2, 2014

Personalized Medicine World Conference (PMWC) 2015
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
The Computer History Museum, Mountain View, CA
January 25, 2015
American Society for Clinical Oncology Annual Meeting
“Predicting Response in Triple-Negative and HER2-Positive Breast Cancer: Unlocking Pieces to Solve the Puzzles”
Chicago, Illinois
May 31, 2015

2015 Canadian Breast Cancer Symposium
“Targeting Breast Cancer: Applying the Lessons of the Past for the New Generation of Drugs”
Toronto, Canada
June 18, 2015

11th National Cancer Research Institute (NCRI) Cancer Conference
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Liverpool, UK
November 3, 2015

UCLA/TRIO-US Annual Conference
“The TRIO Translational Research Model”
Lake Arrowhead, California
November 7, 2015

2015 San Antonio Breast Cancer Symposium
“Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC®T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients”
San Antonio, TX
December 11, 2015

2016 Grupo Español de Investigación en Cáncer de Mama (GEICAM) – Spanish Breast Cancer Group International Congress
“CDK 4-6 Inhibition in Breast Cancer”
Madrid, Spain
February 20, 2016

12th UC San Diego Moores Cancer Center Industry/Academia Translational Oncology Symposium
“Keynote Presentation”
La Jolla, CA
February 25, 2016

Nobel Forum, Karolinska Institutet
Frontiers in Cancer Research and Therapy Symposium
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Stockholm, Sweden
February 26, 2016

American Surgical Association Forum: Cancer Research in the 21st Century
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Chicago, IL
April 15, 2016

Cancer Research Institute of Northern Alberta (CRINA)
The Canada Gairdner Symposium – Cancer Discovers: Molecules to Man
“Cancer Discoveries: Molecules to Man (Public Lecture)”
Edmonton, Canada
May 25, 2016

Institute for Research in Immunology and Cancer – Université de Montréal
The Cell Cycle: From Mechanisms to Therapy
“Targeting the CDK/Rb Axis in Breast Cancer”
Montreal, Canada
June 2, 2016

2016 American Society of Clincial Oncology
“PALOMA-2: Primary Results from a Phase III Trial of Palbociclib (P) with Letrozole (L) Compared with Letrozole Alone in Postmeopausal Women with ER+/HER2- Advanced Breast Cancer (ABC)”’
Chicago, IL
June 6, 2016

UK Breast Cancer Research Symposium 2016
Plenary Session and Concluding Remarks
London, England
July 23, 2016

10th Annual Mid-America Cancer Symposium
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Wichita, KS
August 13, 2016

The Annual Laurence & Jean DeLynn Lecture
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
Morgantown, West Virginia
September 7, 2016

UCLA/TRIO-US Annual Conference
“The TRIO Translational Research Model”
Lake Arrowhead, California
September 24, 2016

University of Toronto Centre of Pharmaceutical Oncology Research Symposium
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Toronto, Canada
October 13, 2016

14th Chinese Breast Cancer Conference/11th Shanghai International Breast Cancer Symposium
“Use of CDK Inhibitors in Human Breast Cancers: Biologic and Therapeutic Implications”
Shanghai, China
October 22, 2016

Roche’s 4th Institute of Breast Cancer: The Science and Art of Patient Management
“Molecular Diversity of Human Breast Cancers: Biologic and Therapeutic Implications”
Shanghai, China
October 23, 2016

UCSF Symposium
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
San Francisco, CA
November 17, 2016

American Association for Cancer Research
“Targeting the Cyclin D: CDK 4/6 Pathway in ER + Breast Cancer: Opportunities and Challenges”
Washington DC
April 4, 2017

9th Annual Association of American Cancer Institute’s Clinical Research Initiative Meeting
“Managing Trials at Affiliate Sites”
Chicago, IL
July 12th, 2017

16th Annual International Congress on the Future of Breast Cancer
“Translational Science That Will Advance Breast Cancer Care”
San Diego, CA
July 14th, 2017

11th Annual Mid-America Cancer Symposium
“Breast Cancer: New Advances in Breast Cancer Management”
Wichita, KS
August 26, 2017

UCLA/TRIO-US Annual Conference
“The TRIO Translational Research Model”
Lake Arrowhead, California
September 9, 2017

Johns Hopkins Dale Lecturer 2017
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Baltimore, MD
October 10, 2017

Mass General Cancer Center Grand Rounds
“Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications”
Boston, MA
October 12, 2017

Montreal Invitation Visiting Speakers Series 2017
“Individualizing Treatment Options in Advanced ER-Positive Breast Cancer”
Montreal, Canada
October 17-19, 2017

Susan G. Komen® Brinker Award for Scientific Distinction in Clinical Research
“Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications”
San Antonio, TX
December 6, 2017

St. Mary’s Medical Center Grand Rounds
“Personalized Medicine – Breakthrough Treatments – Current Trends”
Grand Junction, CO
January 23, 2018

St. Mary’s Community Conversation
“Personalized Medicine – Breakthrough Treatments – Current Trends”
Grand Jucntion, CO
January 23, 2018

PUBLICATION/BIBLIOGRAPHY:

RESEARCH PAPERS

RESEARCH PAPERS (PEER REVIEWED)

A. RESEARCH PAPERS – PEER-REVIEWED

1. Slamon DJ: Protective effect of the double-stranded polyribonucleotide, poly I:C, against rat erythroblastosis virus. J Natl Cancer Inst 5:851-863, 1973.

2. Slamon DJ: Hemolytic anemia induced by murine leukemia virus: Possible mechanisms of hemolysis and effects of an interferon inducer. J Natl Cancer Inst 55:329-338, 1975.

3. Muller R, Slamon DJ, Tremblay JM, Cline MJ, Verma IM: Differential expression of cellular oncogenes during pre and postnatal development of the mouse. Nature 299:660-664, 1982.

4. Bar-Eli M, Mercola KE, Slamon DJ, Mauritzson N, Stang HD, Cline MJ: Insertion of drug resistance genes in animals. J Cell Physiol Suppl. 1982; 1:213-7.

5. Mercola KE, Bar-Eli M, Stang HD, Slamon DJ, Cline MJ: Insertion of new genetic information into bone marrow cells of mice: comparison of two selectable genes. Ann N Y Acad Sci. 1982; 397:272-80.

6. Muller R, Slamon DJ, Adamson ED, Tremblay JM, Muller D, Cline MJ, Verma I: Transcription of c-onc genes, c-ras and c-fms during mouse development.. Mol Cell Biol 3:1062-1069, 1983.

7. Slamon DJ, deKernion JB, Verma IM, Cline MJ: Expression of cellular oncogenes in human malignancies. Science 224:256-262, 1984.

8. Slamon DJ, Cline MJ: Expression of cellular oncogenes during embryonic and fetal development of the mouse. Proc Natl Acad Sci USA 81:7141-7145, 1984.

9. Slamon DJ, Shimotohno K, Cline MJ, Golde DW, Chen ISY: Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science 226:61-65, 1984.

10. Slamon DJ, Press MF, Murdock DC, Souza LM, Cline MJ, Golde DW, Gasson JC, Chen ISY: Studies of the putative transforming protein of the human T-cell leukemia virus, Type I. Science 228:1427-1430, 1985.

11. Tanaka T, Slamon DJ, Cline MJ: Efficient generation of antibodies to oncoproteins using synthesized peptide antigens. Pro Natl Acad Sci 82:3400-3404, 1985.

12. Wachsman W, Slamon DJ, Shimotohno K, Golde DW, Chen ISY: The human T-cell leukemia virus x gene. Cancer Res 45:4550-4552, 1985.

13. Chen ISY, Slamon DJ, Rosenblatt JD, Shah N, Quan SG, Wachsman W: The x gene is essential for HTLV replication. Science 229:54-58, 1985.

14. Shimotohno K, Miwa M, Slamon DJ, Chen ISY, Hishino, H, Tarano M, Fujino M, Sugimura T: Identification of new gene products coded from x regions of human T-cell leukemia viruses. Proc Natl Acad Sci 85:302-306, 1985.

15. Tanaka T, Slamon DJ, Battifora H, Cline MJ: Expression of p21 ras oncoproteins in human cancers. Cancer Res 46:1465-1470, 1986.

16. Shah NP, Wachsman W, Souza L, Cann AJ, Slamon DJ, Chen ISY: Comparison of the trans-activation capabilities of the human T-cell leukemia virus type I and II x proteins. Mol Cell Biol 6:3626-3631, 1986.

17. Slamon DJ, Boone TC, Seeger RC, Keith DE, Chazin V, Lee HC, Souza LM: Identification and characterization of the protein encoded by the human N-myc oncogene. Science 232:768-772, 1986

18. Chan JY, Slamon DJ, Nimer SD, Golde DW, Gasson JC: Regulation of expression of human granulocyte-macrophage colony-stimulating factor (GM-CSF). Proc Natl Acad Sci 83:8669-8673, 1986.

19. Slamon DJ, Boone TC, Murdock DC, Keith DE, Press MF, Larson RA, Souza LM: Studies of the human c-myb gene and its product in human acute leukemias. Science 233:347-351, 1986.

20. Tanaka T, Ida N, Shimoda H, Waki C, Slamon DJ, Cline MJ: Organ specific expressions of ras oncoproteins during growth and development of the rat. Mol Cell. Biochem 70:97-104, 1986.

21. Wachsman W, Cann AJ, William JL, Slamon DJ, Souza LM, Shah NP, Chen, ISY: HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes. Science 235:674-677, 1986.

22. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I: Expression of a multi drug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269, 1987.

23. Tanaka T, Ida N, Waki C, Shimoda H, Slamon DJ, Cline MJ: Cell type-specific expression of c-ras gene products in the normal rat. Mol Cell Biochem 75:23-32, 1987.

24. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.

25. Slamon DJ: Proto-oncogenes and human cancers. New Engl J Med 317:955-957, 1987.

26. McGuire WL, Johnson BE, Seeger RC, Slamon DJ: Oncogenes in clinical cancer – a panel discussion. Breast Cancer Res Treat. 10(3):217-27, 1987.

27. Wada RK, Seeger RC, Brodeur GM, Slamon DJ, Rayner SA, Tomayko M, Reynolds CP: Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. Prog Clin Biol Res. 271:57-69, 1988.

28. Rosenblatt JD, Cann AJ, Slamon DJ, Smalberg IS, Shah NP, Fujii J, Wachsman W, Chen IS. HTLV-II transactivation is regulated by the overlapping tax/rex nonstructural genes. Science. 240(4854):916-9, 1988.

29. Tanaka T, Slamon DJ, Shimoda H, Waki C, Kawaguchi Y, Tanaka Y, Ida N: Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with patient’s prognosis. Cancer Res 48:1030-1034, 1988.

30. Williams AE, Fang CT, Slamon DJ, Poiesz BJ, Sandler SG, Darr II, WF, Shulman G, McGowan EI, Douglas DK, Bowman RJ, Peetoom F, Kleinman SH, Lenes B, Prince HE, Dodd RY: Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors. Science 240:643-646, 1988.

31. Fang CT, Williams AE, Sandler SG, Slamon DJ, Poiesz BJ: Detection of antibodies to human T-lymphotropic virus type I (HTLV-I). Transfusion 28:179-183, 1988.

32. Norman JT, Boyle W, Bohman RE, Fischman G, Bowen JW, McDonough A, Slamon DJ, Fine LG: Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasia. Proc Natl Acad Sci USA. 85:6768-6772, 1988.

33. Slamon DJ, Clark GM: Amplification of c-erbB-2 and aggressive human breast tumors? Science 240:1796-1798, 1988.

34. Slamon DJ, Boyle WJ, Keith DE, Press MF, Golde DW, Souza LM: Subnuclear localization of the trans-activating protein of the human T-cell leukemia virus type I. J Virol 62:680-686, 1988.

35. McGuire WL, Johnson BE, Seeger RC, Slamon DJ: Oncogenes in clinical cancer – a panel discussion. Breast Cancer Research and Treatment 10:217-227, 1988.

36. Wada RK, Seeger RC, Brodeur GM, Slamon DJ, Rayner SA, Tomayko MM, Reynolds CP: Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. Prog Clin Biol Res 271:57-69, 1988.

37. Seeger RC, Wada R, Brodeur GM, Moss TJ, Bjork RL, Sousa L, Slamon DJ: Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 271:41-49, 1988.

38. Rosenblatt JD, Cann AJ, Slamon DJ, Smalberg IS, Shah NP, Fuji J, Wachsman W, Chen ISY: HTLV-II transactivation is regulated by two overlapping tax/rex nonstructural genes. Science 240:916-919, 1988.

39. Moss TJ, Law YM, Slamon DJ, Brodeur GM, Seeger RC: N-myc protein expression by neuroblastoma cells that have metastasized to bone marrow. Prog Clin Biol Res 271:91-101, 1988.

40. Glaser JB, Coleman P, Slamon DJ, Papsidero L, Ehrlich G, Poiesz BJ, Duggan D: Prevalence of HTLV-I and HIV infection among white parenteral drug abusers. J. AIDS, 1(4):415-417, 1988.

41. Triche TJ, Cavazzana AO, Navarro S, Reynolds CP, Slamon DJ, Seeger RE: N-myc protein expression in small round cell tumors. Pro Clin Biol Res. 271:475-485, 1988.

42. Kastan MB, Slamon DJ, Civin CI: Expression of protooncogene c-myb in normal human hematopoietic cells. Blood 73:1444-1451, 1989.

43. Erlich GD, Davey FR, Kirshner JJ, Sninsky JJ, Kwok S, Slamon DJ, Kalish R, Poiesz BJ: A polyclonal CD4+ and CD8+ lymphocytosis in a patient doubly infected with HTLV-I and HIV-1: A clinical and molecular analysis. Am J Hematol 30:128-139, 1989.

44. Reissmann PT, Simon MF, Lee WH, Slamon DJ: Studies of the retinoblastoma gene in human sarcomas. Oncogene 4:839-843, 1989.

45. Anderson D, Epstein JS, Lee TH, Larimore MD, Saxinger C, Kalyanaraman VS, Slamon DJ, Parks W, Poiesz BJ, Pierik LT, Lee H, Montagna R, Roche PA, Williams A, Blatner W: Serological confirmation of Human T-Lymphotripic Virus Type-I Infection in healthy blood and plasma donors. Blood 74:2585-2591, 1989.

46. Erlich GD, Glaser JB, Abbot MA, Slamon DJ, Keith D, Sliwkowski M, Brandis J, Keitelman E, Teramoto Y, Papsidero L, Simpkins H, Sninsky JJ, Poiesz, BJ: Detection of anti-HTLV-I tax antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals. Blood 74(3):1066-1072, 1989.

47. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.

48. Bacus S, Bacus J, Slamon DJ, Press MF: HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med 114:164-169, 1990.

49. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A: Expression of the p185 encoded by HER-2 oncogene in normal and transformed human tissues. Int J Cancer 45:457-461, 1990.

50. Read LD, Keith D, Slamon DJ, Katzenellenbogen B: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947-3951, 1990.

51. Press MF, Cordon-Cardo C, Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953-962, 1990.

52. Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon DJ, Lippman ME: Direct interaction of a ligand for the erbB-2 oncogene product with the EGF receptor and p185erbB-2. Science 249:1552-1555, 1990.

53. Miller CW, Abdulkarim A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler PH: Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50:7950-7954, 1990.

54. Chiba I, Takahashi T, Nau M, D’Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone, D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minna JD (for the Lung Cancer Study Group): Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603-1610, 1990.

55. Slamon DJ: Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest. 8:(2):253, 1990.

56. Hawkins RA, Hoh C, Dahlbom M, Choi Y, Glaspy J, Tse N, Slamon D, Chen B, Messa C, Maddahi J, et al.: PET cancer evaluations with FDG. J Nucl Med. 32(8):1555-8, 1991.

57. Giovanella BC, Vardeman DM, Williams LJ, Taylor DJ, de Ipolyi PD, Greeff PJ, Stehlin JS, Ullrich A, Cailleau R, Slamon DJ, Gary Jr., HE: Heterotransplantation of human breast carcinomas in nude mice: Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer 47:66-71, 1991.

58. Paterson MC, Dietrich KD, Danyluk J, Paterson AHG, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon DJ, Fourney RM: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51:556-567, 1991.

59. Strohmeyer T, Peter S, Hartmann M, Munemitsu S, Ackermann R, Ullrich A, Slamon DJ: Expression of the hst-1 and c-kit proto-oncogenes in human testicular germ cell tumors. Cancer Res 51:1811-1816, 1991.

60. Tanaka T, Slamon DJ, Shimada H, Shimoda H, Fujisawa T, Ida N, Seeger RC: A Significant Association of Ha-ras p21 in Neuroblastoma Cells with Patient Prognosis. A Retrospective Study of 103 Cases. Cancer 68:1296-1302, 1991.

61. Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R, Slamon D: Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci 88:6662-6666, 1991.

62. Slamon DJ: Expression of the nm23 gene and breast cancer prognosis. J Nat Cancer Inst 83:229-231, 1991.

63. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino Jr., MA, Ullrich A, Slamon DJ: Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic. J Clin Immunol 11:117-127, 1991.

64. Aboulafia DM, Mitsuyasu RT, Slamon DJ: Human T-Cell Leukemia Virus Infection in Non-Intravenous Drug Using HIV Seropositive Men in Los Angeles. AIDS Res and Hum. Retr 7:3, 333-336, 1991.

65. Tommasi S, Paradiso A, Mangia A, Barletta A, Simone G, Slamon DJ, de Lena M: Biological Correlation between HER-2/neu and Proliferative Activity in Human Breast Cancer. Anti Cancer Research 11:1395-1400, 1991.

66. Aboulafia DM, Bennett C, Koga H, Keith D, Slamon DJ: Human T-Cell Leukemia Virus Type I/II (HTLV-I/II) Serologic Testing: The Importance of Assaying for the Full Complement of Viral Antigens. Viral. Immunol 5:(2)105-111, 1992.

67. De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press M: Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein. Cancer Res 52:1916-1923, 1992.

68. Chazin VR, Kaleko M, Miller AD, Slamon DJ: Transformation Mediated by the Human HER-2 Gene Independent of the Epidermal Growth Factor Receptor. Oncogene 7:1859-66, 1992.

69. Aboulafia DM, Feigal E, Vranzian K, Bennett C, Blattner W, Moss A, Slamon D: Human T cell leukemia virus (HTLV-I/II) serodiagnostic testing: disparate results among a cohort of intravenous drug users. AIDS Res Hum Retroviruses. 9(10):1043-50, 1993.

70. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, Stram D, Slamon DJ, Steeg PS: Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 8:855-865, 1993.

71. Reissmann PT, Koga H, Takahashi R, Figlin RF, Holmes EC, Cordon-Cardo C, Slamon DJ: Inactivation of the Retinoblastoma Susceptibility Gene in Non-Small Cell Lung Cancer. Oncogene 8:1913-1919, 1993.

72. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ: HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993.

73. Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howell SB: Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol 11:(5)891-898, 1993.

74. Pietras RJ, Fendly B, Chazin V, Pegram M, Howell S, Slamon D: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian carcinoma cells. Oncogene 9:(7) 1829-1838, 1994.

75. Press M, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994.

76. Fleischhacker M, Strohmeyer T, Imai Y, Slamon DJ, Koeffler HP: Mutations of the p53 gene are not detectable in human testicular tumors. Modern Pathology 7:(4)435-439, 1994.

77. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP: p53 Mutations and MDM-2 Amplification in Renal Cell Cancers. Modern Pathology, 7:(7)766-770, 1994.

78. Ronco LV, Silverman SL, Wong SG, Slamon DJ, Park LS, Gasson JC: Identification of Conserved Amino Acids in the Human Granulocyte-Macrophage Colony-stimulating Factor Receptor  Subunit Critical for Function. Evidence for formation of a heterodimeric receptor complex prior to ligand binding. J Biol Chem 269:(1)277-283, 1994.

79. Karlan BY, Jones J, Slamon DJ, Lagasse LD: Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol 53:70-77, 1994.

80. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Bank J, James W, Slamon DJ, Batsakis JG, El-Naggar AK: Amplification and Overexpression of HER-2/neu in Carcinomas of the Salivary Gland: Correlation with Poor Prognosis. Cancer Res 54(21): 5675-5682, 1994.

81. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A, Minna J: p53 Immunostaining Positivity is Associated With Reduced Survival and is Imperfectly Correlated With Gene Mutations in Resected Non-small Cell Lung Cancer. A Preliminary Report of LCSG 871. Chest 106:377S-381S, 1994.

82. Strohmeyer T, Reese D, Press M, Ackermann R, Hartmann M, Slamon D: Expression of the c-KIT photo-oncogene and its Ligand Stem Cell Factor (SCF) in Normal and Malignant Human Testicular Tissue. J of Urology 153:511-515, 1995.

83. Yates KE, Lynch MR, Wong SG, Slamon DJ, Gasson JC: Human c-FES is a Nuclear Tyrosine Kinase. Oncogene 10:1239-1242, 1995.

84. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 Tyrosine Kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995.

85. Levin WJ, Press MF, Gaynor RB, Sukhatme VP, Boone TC, Reissmann PT, Figlin RA, Holmes EC, Souza LM, Slamon DJ and the Lung Cancer Study Group: Expression patterns of immediate early transcription factors in human non-small cell lung cancer. Oncogene 11:1261-1269, 1995.

86. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky BS, Gamagami P, Slamon DJ: Prognostic classification of breast ductal carcinoma-in-situ: The Lancet 345:1154-1157, 1995.

87. Kotts CE, Su FM, Leddy C, Dodd T, Scates S, Shalaby MR, Wirth CM, Giltinan D, Schroff RW, Fritzberg AR, Shepard HM, Slamon DJ, Hutchins BM: 186Re-Labeled Antibodies to p185HER2 as HER2-Targeted Radioimmunopharmaceutical Agents: Comparison of Physical and Biological Characteristics with 125I and 131I-Labeled Counterparts. Cancer Biotherapy and Radiopharmaceuticals 11(2):133-144, 1996.

88. Li B, Ouyang B, Pan H, Reissmann PT, Slamon DJ, Arceci R, Lu L, Dai W: Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. J Biol Chem 271(32):19402-19408, 1996.

89. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and Quantitation of HER-2/neu Gene Amplification in Human Breast Cancer Archival Material Using Fluorescence In Situ Hybridization. Oncogene 13:63-72, 1996.

90. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda JE, Shaughnessy M, Karlan B, Slamon D: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13:1971-1981, 1996.

91. Wilson CA, Payton MN, Pekar SK, Zhang K, Pacifici RE, Gudas JL, Thukral S, Calzone FJ, Reese DM, Slamon D: BRCA1 protein products: antibody specificity… Nat Genet. 13(3):264-5, 1996.

92. MacGrogan D, Pegram M, Slamon D, Bookstein R: Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene. 15(9):1111-4, 1997.

93. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The Effect of HER-2/neu Overexpression on Chemotherapeutic Drug Sensitivity in Human Breast and Ovarian Cancer Cells. Oncogene 15:537-547, 1997.

94. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Nagger A, Slamon DJ, Phillips RN, Ross JS, Wolman SF, Flom KJ: HER-2/neu Gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 8(15):2894-2904, 1997.

95. Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ, Calzone FJ: Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-11b. Oncogene 14:1-16, 1997.

96. Pegram MD, Lipton A, Hayes D, Weber B, Baselga J, Tripathy D, Baly D, Baughman S, Twaddell T, Glaspy J, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER-2/neu monoclonal antibody (rhuMAb HER2) plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8): 2659-2671, 1998.

97. Paquette RL, Gonzales E, Yoshimura R, Tran L, Choi R, Baldwin G, Slamon DJ, Glaspy J: Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media. J Hematother 7(6):481-491, 1998.

98. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17(11):3052-65, 1998.

99. Challita-Eid PM, Penichet ML, Shin SU, Poles T, Mosammaparast N, Mahmood K, Slamon DJ, Morrison SL, Rosenblatt JD: A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol 160(7):3419-26, 1998.

100. Pietras RJ. Pegram MD, Finn RS, Maneval DA, Slamon DJ: Remission of Human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235-2249, 1998.

101. Landgraf R, Pegram M, Slamon DJ, Eisenberg D: Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. Biochemistry 3:37(9):3220-3228, 1998.

102. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan BY, Chen J-J, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ: Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nature Genetics 21:236-240, 1999.

103. Pegram M, Hsu S, Pietras RJ, Sliwkowski M, Beryt M, Coombs D, Baly D, Kabbinavar K, Slamon DJ: Inhibitory Effects of Combinations of HER-2/neu Antibody and Chemotherapeutic agents used for Treatment of Human Breast Cancers. Oncogene 18:2241-2251, 1999.

104. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ: Monoclonal Antibody to HER-2/neu Receptor Modulates Repair of Radiation-Induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing this Oncogene. Cancer Res 59:1347-1355, 1999.

105. Pegram MD, Slamon DJ: Combination Therapy With Trastuzumab (Herceptin) and Cisplatin for Chemoresistant Metastatic Breast Cancer: Evidence for Receptor-Enhanced Chemosensitivity. Semin Oncol 26(4): Suppl. 12, 89-95 (August) 1999.

106. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational Study of the Efficacy and Safety of Humanized Anti HER-2 Monoclonal Antibody in Women who have HER-2 Overexpressing Metastatic Breast Cancer that has Progressed after Chemotherapy for Metastatic Disease. J Clin Oncol 17(9):2639-2648, 1999.

107. Oh JJ, Grosshans DR, Wong SG, Slamon DJ: Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res 27:4008-4017, 1999.

108. Aguilar Z, Akita RW, Finn RS, Ramos LB, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ: Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian Epithelial Cells. Oncogene 18:(44):6050-6062, 1999.

109. Lopez AM, Pegram MD, Slamon DJ, Landaw EM: A Model-based approach for assessing in vivo combination therapy interactions. PNAS 96(23):13023-13028, 1999.

110. Reissman PT, Koga H, Figlin RA, Holmes EC, Slamon DJ, The Lung Cancer Study Group: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. J. Cancer Res Clin Oncol 125:61-70, 1999.

111. Slamon D: Biologic Approaches to Managing Advanced Breast Cancer. Cancer Control. 6(5 Suppl 2):7-11, 1999.

112. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ: Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol. 35(6):597-602, 2000.

113. Slamon D: Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs. 4(Sa):24-9, 2000.

114. Strawn LM, Kabbinavar F, Schwartz DP, Mann E, Shawver LK, Slamon DJ, Cherrington JM: Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. Clin Cancer Res 6(7):2931-2940, 2000.

115. Pegram M, Slamon DJ: Biological Rationale for HER2/neu (c-erbB2) as a Target for Monoclonal Antibody Therapy. Semin Oncol 27(5): Suppl 9:13-19, 2000.

116. Pauletti G, Dandekar S, Rong H-M, Ramos L, Peng H-J, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18(21):3651-3664, 2000.

117. Pegram MD, Lopez A, Konecny G, Slamon DJ: Trastuzumab and Chemotherapeutics: Drug Interactions and Synergies. Semin Oncol 27(6): Suppl 11:21-25; discussion 92-100, 2000.

118. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA: Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood 96(7): 2385-2390, 2000.

119. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton LA: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344(11):783-792, 2001.

120. Poiesz BJ, Papsidero LD, Ehrlich G, Sherman M, Dube S, Poiesz M, Dillon K, Ruscetti FW, Slamon D, Fang C, Williams A, Duggan D, Glaser J, Gottlieb A, Goldberg J, Ratner L, Phillips P, Han T, Friedman-Kien A, Siegal F, Rai K, Sawitsky A, Sheremata LW, Dosik H, Cunningham C, Montagna R: Prevalence of HTLV-I-associated T-cell lymphoma. Am J Hematol 66(1):32-38, 2001.

121. Konecny G, Untch M, Pihan A, Kimmig, R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M: Association of Urokinase-Type Plasminogen Activator and its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer. Clin Can Res 7:1743-1749, 2001.

122. Bergman, I, Barmada MA, Griffin JA, Slamon DJ: Treatment of Meningeal Breast Cancer Xenografts in the Rat Using an Anti-P185/HER2 Antibody. Clin Can Res 7:2050-2056, 2001.

123. Aguilar Z, Slamon DJ: The Transmembrane Heregulin Precursor Is Functionally Active. J Biol Chem 276(47):44099-44107, 2001.

124. Fejzo SM, Slamon DJ: Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins. Am J Pathol 159:1645-1650, 2001.

125. Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS, Bundred NJ: Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg. 88(3):412-418, 2001.

126. Arboleda MJ, Slamon DJ: Signal transduction : a technical overview. Methods Mol Med. 39:555-65, 2001.

127. Lackey DB, Groziak MP, Sergeeva M, Beryt M, Boyer C, Stroud RM, Sayre P, Park JW, Johnston P, Slamon D, Shepard HM, Pegram M: Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem Pharmacol. 61(2):179-89, 2001.

128. Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M: Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res. 7(8):2448-57, 2001.

129. Singer E, Landgraf R, Horan T, Slamon D, Eisenberg D: Identification of a heregulin binding site in HER3 extracellular domain. J Biol Chem. 276(47):44266-74, 2001.

130. Konecny G, Untch M, Slamon D, Beryt M, Kahlert S, Felber M, Langer E, Lude S, Hepp H, Pegram M: Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Res Treat. 67(3):223-33, 2001.

131. Schoenberg Fejzo M, Slamon DJ: Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol. 159(5):1645-50, 2001.

132. Konecny G, Fritz M, Untch M, Lebeau A, Felber M, Lude S, Beryt M, Hepp H, Slamon D, Pegram M: HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res Treat. 69(1):53-63, 2001.

133. Elkas JC, Baldwin RL, Pegram M, Tseng Y, Slamon D, Karlan BY: A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol. 87(2):200-6, 2002.

134. Oh JJ, West AR, Fishbein MC, Slamon DJ: A Candidate Tumor Suppressor Gene, H37, from the Human Lung Cancer Tumor Suppressor Locus 3p21.3. Cancer Res 62:3207-3213, 2002.

135. Konecny G, Slamon DJ: HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology. 16(11):1576-1578, 2002.

136. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. J Clin Oncol. 20(3):719-726, 2002.

137. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA: Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. Exp Hematol. 4:374-380, 2002.

138. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin Oncol. 20(14):3095-3105, 2002.

139. Osoba D, Slamon DJ, Burchmore M, Murphy M: Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 20(14):3106-3113, 2002.

140. Namazie A, Alavi S, Olopade OI, Pauletti G. Aghamohammadi N, Aghamohammadi M, Gornbein JA, Calcaterra TC, Slamon DJ, Wang MB, Srivatsan ES: Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 112(3):472-81, 2002.

141. Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M: Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Therapy 9:567-572, 2002.

142. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M: A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Therapy 9:553-566, 2002.

143. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 95(2):142-53, 2003.

144. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ: Overexpression of AKT2/Protein Kinase Bbeta Leads to Up-Regulation of beta 1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells. Cancer Res. 63(1):196-206, 2003.

145. Tripathy D, Slamon DJ, Cobleigh M. Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 22(6):1063-70, 2004.

146. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Guitierrez J. Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD: Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 10(5):1706-16, 2004.

147. Oh JJ, Fishbein MC, Boctor B, Jimenez CA, Lopez R, Slamon DJ: Evaluation of H37, a candidate 3p21.3 tumor suppressor gene, as a therapeutic and diagnostic marker in lung cancer. Chest. 125(5 Suppl):102S-3S, 2004.

148. Pegram MD, Konecny, GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ: Rational Combinations of Trastuzumab with Chemotherapeutic Drugs Used in the Treatment of Breast Cancer. JNCI 96(10):739-49, 2004.

149. Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidmann H, du Bois A, Olbright S, Steinfeld D, Mobus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Janicke F, Slamon DJ. HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 96(15):1141-51, 2004.

150. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ. Results of Two Open-Label Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. JNCI 95(10):759-69, 2004.

151. Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biol Ther. 3(12):1243-9, 2004.

152. Slamon DJ: The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors. Oncologist. 9(Suppl 3):1-3, 2004.

153. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 7(4):R436-43, 2005.

154. Carlson A, Yates KE, Slamon DJ, Gasson JC: Spatial and temporal changes in the subcellular localization of the nuclear protein-tyrosine kinase, c-Fes. DNA Cell Biol. 24(4):225-34, 2005.

155. Carlson A, Berkowitz JM, Browning D, Slamon DJ, Gasson JC, Yates KE: Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias. DNA Cell Biol. 24(5):311-6, 2005.

156. Oh JJ, Boctor B, Jimenez CA, Lopez RC, Razfar A, Slamon DJ: Use of low-melting-point primers for bisulfite genomic sequencing: analysis of the H37 lung cancer tumor suppressor gene promoter. Anal Biochem. 343(2):347-9, 2005.

157. Mass RD, Press ME, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ: Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab. Clin Breast Cancer. 6(3):240-6, 2005.

158. Wilson CA, Slamon DJ: Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways. J Natl Cancer Inst. 97(17):1238-9, 2005.

159. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P: Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 16(11):1772-7, 2005.

160. Press MF, Sauter G, Bernstein L, Villalobos EI, Mirlacher M. Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ: Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11(18):6598-607, 2005.

161. Byrne JA, Balleine RL, Fejzo MS, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defaxio A: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer. 117(6):1049-54, 2005.

162. Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ: HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res. 7(6):R1058-79, 2005.

163. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ: Surviving expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 17(4):597-604, 2006.

164. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 24(18):2786-92, 2006.

165. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66(3):1630-9, 2006.

166. Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 24(12):1831-8, 2006.

167. Slamon DJ, Romond EH, Perez EA, CME Consultants, Inc.: Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol;4(3):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10, 2006.

168. Oh JJ, Razfar A, Delgado I, Reed RA, Malkina A, Boctor B, Slamon DJ: 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis. Cancer Res. 2006; 66(7):3419-27.

169. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P. Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the scr and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 105(3):319-26, 2007.

170. Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW: First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res. 13(4):1238-45, 2007.

171. Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, Courneya KS, Slamon DJ, Mackey JR: Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracyline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev. 16(5):1026-1031, 2007.

172. Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G, Visco FM: Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer, 7(4):309-15, 2007.

173. Oh JJ, Koegel AK, Phan DT, Razfar A, Slamon DJ: The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancers. Lung Cancer. 58(1):7-14, 2007.

174. Milstein M, Mooser CK, Hu H, Fejzo M, Slamon D, Goodglick L, Dry S, Colicelli J: RIN1 is a breast tumor suppressor gene. Cancer Res. 67(24):11510-6, 2007.

175. Britten CD, Kabbinavar FF, Hecht JR, Bello CL, Li Jim, Baum C, Slamon DJ: A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks followed by a 1-week off period. Cancer Chemother Pharmacol. 61(3):515-24, 2008.

176. Oh JJ, Boctor BN, Jimenez CA, Lopez R, Koegel AK, Taschereau EO, Phan DT, Jacobsen SE, Slamon DJ: Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus. Hum Genet. 123(1):55-64, 2008.

177. Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgame JV: Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res. 10(1):R3, 2008.

178. Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ, Kwon O, Tamanoi F: Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem. 283(15):9571-9, 2008.

179. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC: Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer. 98(6):1076-84, 2008.

180. Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler P, Karlan BY: ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol. 26(18):2952-8, 2008.

181. Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ: Comprehensive analysis of 20q13 genes in ovarian cancer ADRMI as amplification target. Genes Chromosomes Cancer. 47(10):873-83, 2008.

182. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11(5):R77, 2009.

183. Britten CD, Finn RS, Bosserman LD, Wong SG, Press MF, Malik M, Lum BL, Slamon DJ: A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer. 9(1):16-22, 2009.

184. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IeM: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 174(5):1597-601, 2009.

185. Slamon DJ, Press MF: Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst. 101(9):615-8, 2009.

186. Swaisland HC, Oliver SD, Morris T, Jones HK, Bakhtyari A, Mackey A, McCormick AD, Slamon D, Hargreaves JA, Millar A, Taboada MT: In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers. Xenobiotica. 39(6):444-56, 2009.

187. Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ: Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer. 101(10):1699-708, 2009.

188. Xu J, Huo D, Chen Y, Nwachukwu C, Collins C, Rowell J, Slamon DJ, Olopade OI: CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat. 120(3):593-601, 2010.

189. Fejzo MS, Slamon DJ: Tissue microarrays from frozen tissues-OCT technique. Methods Mol Biol. 664:73-80, 2010.

190. Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV: Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 10:32, 2010.

191. Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ: Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat. 120(2):481-9, 2010.

192. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS: Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 16(5):1509-19, 2010.

193. Oh JJ, Taschereau EO, Koegel AK, Ginther CL, Rotow JK, Isfahani KZ, Slamon DJ: RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. Lung Cancer. 70(3):253-62, 2010.

194. O’Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O’Donovan N, Slamon DJ: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 9(6):1489-502, 2010.

195. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV: FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 70(13):5475-85, 2010.

196. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ: Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther. 9(7):1985-94, 2010.

197. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ: Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia. 12(8):637-49, 2010.

198. Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F: A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer. 10(4):307-12, 2010.

199. Zhu M, Fejzo MS, Anderson L, Dering J, Ginther C, Ramos L, Gasson JC, Karlan BY, Slamon DJ: Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol. 119(2):337-44, 2010.

200. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 330(6001):228-31, 2010.

201. Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O’Donovan N: Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol. 22(1):68-73, 2011.

202. Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 29(2):149-56, 2011.

203. Tap WD, Eilber FC, Ginther C, Dry SM, Reese N, Barzan-Smith K, Chen HW, Wu H, Eilber FR, Slamon DJ, Anderson L: Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer. 50(2):95-112, 2011.

204. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ: Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 29(7):859-67, 2011.

205. Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ: Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 17(6):1591-602, 2011.

206. Fejzo MS, Ginther C, Dering J, Anderson L, Venkatesan N, Konecny G, Karlan B, Slamon DJ: Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK. Genes Chromosomes Cancer. 50(6):434-41, 2011.

207. Zhu M, Saxton RE, Ramos L, Chang DD, Karlan BY, Gasson JC, Slamon DJ: Neutralizing monoclonal antibody to periostin inhibits overian tumor growth and metastatis. Mol Cancer Ther, 10(8):1500-8, 2011.

208. Slamon DJ, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M0C, Sauter G, Von Minckwitz G, Visco F, Bee F, Buyse M, Bendaman B, Taba-Fisch I, Lindsay M-A, Riva A, Crown J (on behalf of the Breast Cancer International Research Group {BCIRG}): Adjuvant trastuzumab in HER-2 Positive Breast Cancer. N Engl J Med, 365(14):1273-83, 2011.

209. Zhu M, Saxton RE, Ramos L, Chang DD, Karlan BY, Gasson JC, Slamon DJ. Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. Mol Cancer Ther. 2011 Aug;10(8):1500-8. doi: 10.1158/1535-7163.MCT-11-0046.

210. Press MF, Gordon MA, Slamon DJ. Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance. J Clin Oncol. 2012 Feb 1;30(4):357-61. doi: 10.1200/JCO.2011.35.1023.
211. Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol. 2012; 14(3-4):65-78.

212. Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 2012 Jan 14;12:16.

213. Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene. 2013 Jan 31;32(5):554-63.

214. Kalous O, Conklin D, Desai AJ, O’Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012 Sep;11(9):1978-87.

215. Finn RS, Aleshin A, Dering J, Yang P, Ginther C, Desai A, Zhao D, von Euw E, Busuttil RW, Slamon DJ. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology. 2013 Jan 8.

216. Fejzo MS, Anderson L, von Euw EM, Kalous O, Avliyakulov NK, Haykinson MJ, Konecny GE, Finn RS, Slamon DJ. Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer. Int J Mol Sci. 2013 Feb 1;14(2):3094-109

217. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O’Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS. Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer. Mol Cancer Ther. 2013 Apr;12(4):509-19.

218. Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) Breast Cancer Res Treat. 2013 Feb;138(1):99-108.

219. Konecny GE, Kolarova T, O’Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Graus Porta D, Anderson L, Shi MM, Yovine A, Slamon DJ. Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells. Mol Cancer Ther. 2013 Feb 26.

220. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8.

221. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Rugaard Jensen M, Quadt C, Liu M, Dubinett SM, Slamon DJ. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013 Mar 14.

222. Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013 Jun;12(6):1002-15.

223. Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Translational Research in Oncology BCIRG 006 Trial Investigators. Oncologist. 2013;18(7):812-8.

224. Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004.

225. Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Res Treat. 2013 Oct;141(3):397-408.

226. Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.Gynecol Oncol. 2013 Dec 22. pii: S0090-8258(13)01385-1.

227. Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett SM, Slamon DJ. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res. Clin. Oncol. 2014 Jan 18.

228. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ, Baylin SB, Zahnow CA, Ahuja N. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014 Feb 15;5(3):587-98.

229. Fasching PA, Weihbrecht S, Haeberle L, Gasparyan A, Villalobos IE, Ma Y, Ekici AB, Wachter DL, Hartmann A, Beckmann MW, Slamon DJ, Press MF. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. Breast Cancer Res Treat. 2014 May;145(1):193-203.

230. Hurvitz SA, Bosserman LD, Chan D, Hagenstad CT, Kass FC, Smith FP, Rodriguez GI, Childs BH, Slamon DJ. Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. Springerplus. 2014 May 12;3:244.

231. Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res. 2014 Jun 1;20(11):2947-58.

232. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.. J Clin Invest. 2014 Jun 2;124(6):2611-25.

233. McDermott MS, Browne BC, Conlon NT, O’Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O’Donovan N. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol Cancer. 2014 Jun 24;13:157.

234. O’Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ. Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. Clin Cancer Res. 2014 Jul 1;20(13):3507-20.

235. Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, Linnartz R, Zubel A, Slamon DJ, Finn RS. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer. 2014 Aug 28.

236. Bilchik AJ, Wainberg ZA, Nissan A, Slamon DJ, Protic M, Avital I, Chen HW, Chen D, Sim M, Elashoff D, Stojadinovic A. Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multicenter Trial. Ann Surg Oncol. 2014 Sep 5.

237. Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014 Sep 30;106(10).

238. Himburg HA, Yan X, Doan PL, Quarmyne M, Micewicz E, McBride W, Chao NJ, Slamon DJ, Chute JP. Pleiotrophin mediates hematopoietic regeneration via activation of RAS. J Clin Invest. 2014 Nov;124(11):4753-8.

239. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35

240. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015 Feb 1;33(4):304-11.

241. Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J, Daraei P, Christofk HR, Hewitt SC, Korach KS, Tontonoz P, Lusis AJ, Slamon DJ, Hurvitz SA, Hevener AL. Estrogen Receptor (ER)α-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression. J Biol Chem. 2015 Feb 27;290(9):5566-81.

242. Stern H, Gardner H, Burzykowski T, Elatre W, O’Brien C, Lackner MR, Pestano GA, Santiago A, Villalobos I, Eiermann W, Pienkowski T, Martin M, Robert NJ, Crown J, Nuciforo P, Bee V, Mackey J, Slamon DJ, Press MF. PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance. Clin Cancer Res. 2015 Feb 3.

243. Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O’Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Res Treat. 2015 Feb; 149(3):669-80.

244. Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roché H, Sánchez-Rovira P, Pienkowski T, Seguí Palmer MÁ, Li A, Sun YN, Pickett CA, Slamon DJ. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast. 2015 Mar 4. pii: S0960-9776(14)00192-1.

245. Fejzo MS, Anderson L, Chen HW, Anghel A, Zhuo J, Anchoori R, Roden R, Slamon DJ. ADRM1-amplified metastasis gene in gastric cancer. Genes Chromosomes Cancer. 2015 Jun 6. doi: 10.1002/gcc.22262. [Epub ahead of print]

246. Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015 Jul;16(7):816-29. doi: 10.1016/S1470-2045(15)00051-0. Epub 2015 Jun 16.

247. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Buhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Mergoub T, Chan TA, Baylin SB, Strick R. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015 Aug 27;162(5):974-86. doi: 10.1016/j.cell.2015.07.011.

248. Lu NT, Raizer J, Gabor EP, Liu NM, Vu JQ, Slamon DJ, Barstis JL. Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J Immunother Cancer. 2015 Sep 15;3:41. doi: 10.1186/s40425-015-0084-y. eCollection 2015.

249. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2016 Feb 25;164(5):1073. doi: 10.1016/j.cell.2015.10.020. Epub 2016 Feb 25.

250. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houé V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC–A Randomized Phase III Trial. J Clin Oncol. 2016 Feb 10;34(5):443-51. doi: 10.1200/JCO.2015.62.6598. Epub 2015 Nov 30.

251. Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016 Feb 9;18(1):17. doi: 10.1186/s13058-015-0661-5.

252. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-39. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3.

253. Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D. Statistical controversies in clinical research: statistical significance-too much of a good thing …. Ann Oncol. 2016 May;27(5):760-2. doi: 10.1093/annonc/mdw047. Epub 2016 Feb 9. Review.

254. Bell T, Crown JP, Lang I, Bhattacharyya H, Zanotti G, Randolph S, Kim S, Huang X, Huang Bartlett C, Finn RS, Slamon D. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.. Curr Med Res Opin. 2016 May;32(5):959-65. doi: 10.1185/03007995.2016.1157060. Epub 2016 Mar 2.

255. Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 Jun;27(6):1029-34. doi: 10.1093/annonc/mdw132. Epub 2016 Mar 8.

256. André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O’Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. J Clin Oncol. 2016 Jun 20;34(18):2115-24. doi: 10.1200/JCO.2015.63.9161. Epub 2016 Apr 18.

257. Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, Kim ST, Huang X, Schnell P, Nadanaciva S, Bartlett CH, Slamon DJ. Efficacy and safety of Palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: explanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO18. Breast Cancer Res. 2016 Jun 28;18(1):67. doi: 10.1186/s13058-016-0721-5.

258. Economou, JS, Slamon, DJ, Ribas, A, Phelps, ME. Cancer Research in the 21st Century. Ann Surg. 2016 Aug 17

259. Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. 2016 Aug 29. pii: JCO666693.

260. Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, King K, Koski S, Mulder K, Hiller JP, Scarfe A, Spratlin J, Huang YJ, Khan-Wasti S, Chua N, Sawyer MB. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2016 Oct 13. doi: 10.1001/jamaoncol.2016.3358. [Epub ahead of print]

261. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936.

262. Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, Liang Z, Wu S, Bang YJ, Qin SK, Chung HC, Xu J, Park JO, Jeziorski K, Afenjar K, Ma Y, Estrada MC, Robinson DM, Scherer SJ, Sauter G, Hecht JR, Slamon DJ. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. Mol Cancer Ther. 2017 Jan;16(1):228-238. doi: 10.1158/1535-7163.MCT-15-0887

263. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 2017 Feb 13;31(2):225-239. doi: 10.1016/j.ccell.2017.01.005.

264. Jiang J, Zhao H, Shu W, Tian J, Huang Y, Song Y, Wang R, Li E, Slamon D, Hou D, Du X, Zhang L, Chen Y, Wang Q. An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cells. Sci Rep. 2017 Feb 15;7:42612. doi: 10.1038/srep42612.

265. Fejzo MS, Anderson L, Chen HW, Guandique E, Kalous O, Conklin D, Slamon DJ. Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi. Genes Chromosomes Cancer. 2017 Aug;56(8):589-597. doi: 10.1002/gcc.22459. Epub 2017 May 4.

266. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2017 Apr 6;169(2):361. doi: 10.1016/j.cell.2017.03.036.

267. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.

268. Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G, Bradley R, Brain E, Braybrooke J, Broet P, Bryant J, Burrett J, Cameron D, Clarke M, Coates A, Coleman R, Coombes RC, Correa C, Costantino J, Cuzick J, Danforth D, Davidson N, Davies C, Davies L, Di Leo A, Dodwell D, Dowsett M, Duane F, Evans V, Ewertz M, Fisher B, Forbes J, Ford L, Gazet JC, Gelber R, Gettins L, Gianni L, Gnant M, Godwin J, Goldhirsch A, Goodwin P, Gray R, Hayes D, Hill C, Ingle J, Jagsi R, Jakesz R, James S, Janni W, Liu H, Liu Z, Lohrisch C, Loibl S, MacKinnon L, Makris A, Mamounas E, Mannu G, Martín M, Mathoulin S, Mauriac L, McGale P, McHugh T, Morris P, Mukai H, Norton L, Ohashi Y, Olivotto I, Paik S, Pan H, Peto R, Piccart M, Pierce L, Poortmans P, Powles T, Pritchard K, Ragaz J, Raina V, Ravdin P, Read S, Regan M, Robertson J, Rutgers E, Scholl S, Slamon D, Sölkner L, Sparano J, Steinberg S, Sutcliffe R, Swain S, Taylor C, Tutt A, Valagussa P, van de Velde C, van der Hage J, Viale G, von Minckwitz G, Wang Y, Wang Z, Wang X, Whelan T, Wilcken N, Winer E, Wolmark N, Wood W, Zambetti M, Zujewski JA. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan;19(1):27-39. doi: 10.1016/S1470-2045(17)30777-5. Epub 2017 Dec 11.

269. Fejzo MS, Sazonova OV, Sathirapongsasuti JF, Hallgrímsdóttir IB, Vacic V, MacGibbon KW, Schoenberg FP, Mancuso N, Slamon DJ, Mullin PM; 23andMe Research Team. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat Commun. 2018 Mar 21;9(1):1178. doi: 10.1038/s41467-018-03258-0.

270. O’Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Mc Nulty A, Marchal C, Kalous O, von Euw E, Hurvitz S, Mockbee C, Slamon DJ. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Mol Cancer Ther. 2018 May;17(5):897-907. doi: 10.1158/1535-7163.MCT-17-0290. Epub 2018 Feb 26.

271. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018 Jun 3:JCO2018789909. doi: 10.1200/JCO.2018.78.9909. [Epub ahead of print]

272. Koutsioumpa M, Chen HW, O’Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A. MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer. Mol Cancer Ther. 2018 Jul;17(7):1430-1440. doi: 10.1158/1535-7163.MCT-17-1049. Epub 2018 Apr 27.

273. Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. J Natl Cancer Inst. 2018 Jul 18. doi: 10.1093/jnci/djy109. [Epub ahead of print]

274. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 Sep;123:91-98. doi: 10.1016/j.lungcan.2018.06.013. Epub 2018 Jun 22.

B. RESEARCH PAPERS-PEER-REVIEWED (IN PRESS)
None

C. RESEARCH PAPERS-PEER-REVIEWED (SUBMITTED)
None

RESEARCH PAPERS (NON-PEER REVIEWED)

D. RESEARCH PAPERS – NON-PEER REVIEWED

1. Chen ISY, Golde DW, Slamon DJ, Wachsman W: Comparative studies of HTLV-I and HTLV-II in: Leukemia 1985, UCLA Symposia, Volume 28, Gale RP, Golde DW, Eds. New York, Alan R. Liss, 1985.

E. RESEARCH PAPERS – NON-PEER REVIEWED (IN PRESS)
None

F. RESEARCH PAPERS – NON-PEER REVIEWED (SUBMITTED)
None

CHAPTERS

1. Chen ISY, Golde DW, Slamon DJ, Wachsman W: Comparative studies of HTLV-I and HTLV-II in: Leukemia 1985, UCLA Symposia, Volume 28, Gale RP, Golde DW, Eds. New York, Alan R. Liss, 1985.

2. Rosenblatt J, Wachsman W, Shimotohno K, Slamon DJ, Chen ISY: The comparative molecular biology of HTLV-I and HTLV-II. Proc. Imperial Japanese Cancer Research Fund. M. Miwa, et al. (eds), 177-185, 1985.

3. Aboud M, Golde DW, Wachsman W, Rosenblatt JD, Cann AJ, Gaynor RB, Slamon DJ, Chen ISY: Biology and leukemogenicity of human T-cell leukemia viruses in human cancers. Eds. UCLA Symposium, Park City, Utah, Alan R. Liss, New York, 1986.

4. Chen ISY, Slamon DJ: Diagnosis of human T-cell leukemia virus infection. HIV Detection by Genetic Engineering Methods. Steimer K, Luciw P, Eds. Marcel Dekker, Inc., New York, 275-292, 1989.

5. Park JW, Stagg R, Lewis G.D, Carter P, Maneval D., Slamon DJ, Jaffe H, Shepard HM: Anti-p185HER2 monoclonal antibodies: Biological properties and potential for immunotherapy. Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Dickson RB, Lippman ME, Eds. Kluwer Academic Publishers, Boston. 193-211, 1991.

CHAPTERS (IN PRESS)
None

LETTERS TO THE EDITOR

1. Wilson CA, Payton MN, Pekar SK, Zhang K, Pacifici RE, Gudas JL, Thukral S, Calzone FJ, Reese DM, Slamon D: BRCA1 protein products: antibody specificity. Nat Genet 13(3):264-5, 1996.

REVIEWS

1. Rosenblatt J, Wachsman W, Shimotohno K, Slamon D, Chen IS: The comparative molecular biology of HTLV-I and HTLV-II. Princess Takamatsu Symp. 15:177-85, 1984.

2. Cline MJ, Slamon DJ, Lipsick JS: Oncogenes: implications for the diagnosis and treatment of cancer. Ann Intern Med. 101(2):223-33, 1984.

3. Slamon, DJ, Chen ISY: RNA viruses and human cancer. Infectious Disease Newsletter 5:28-30, 1986.

4. Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ: HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res. 354A:209-21, 1990.

5. Dickson RB, Lippman ME, Slamon D: UCLA colloquium. New insights into breast cancer: the molecular biochemical and cellular biology of breast cancer. Cancer Res. 50(14):4446-7, 1990.

6. Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, Jaffe H, Shepard HM: Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treat Res. 61:193-211, 1992.

7. Strohmeyer TG, Slamon DJ: Proto-oncogenes and tumor suppressor genes in human urological malignancies. J Urol. 151(6):1479-97, 1994.

8. Levin WJ, Casey G, Ramos JC, Arboleda MJ, Reissmann PT, Slamon DJ: Tumor suppressor and immediate early transcription factor genes in non-small cell lung cancer. Chest. 106(6 Suppl):372S-376S, 1994.

9. Reese DM, Slamon DJ: HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 15(1):1-8, 1997.

10. Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 52(1-3):65-77, 1998.

11. Pegram MD, Konecny G, Slamon DJ: The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res. 103:57-75, 2000.

12. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Genentech H0650 study investigators: First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 37 Suppl 1:S25-9, 2001.

13. Nabholtz JM, Slamon D: New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol. 28(1 Suppl 3):1-12, 2001.

14. Slamon D, Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 28(1 Suppl 3):13-9, 2001.

15. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ: First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 61 (Suppl 2):37-42, 2001.

16. Shawver LK, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 1(2):117-23, 2002.

17. Finn RS, Slamon DJ: Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif. 21:223-33, 2003.

18. Konecny GE, Wilson CA, Slamon DJ: Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention? J Natl Cancer Inst. 17:95(24):1813-5, 2003.

19. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ: Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 10(11):3885-96, 2004.

20. Shepard HM, Jin P, Slamon DJ, Pirot Z, Maneval DC: Herceptin. Handb Exp Pharmacol. (181):183-219, 2008.

21. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 27(8):1323-33, 2009.

EDITORIALS

1. Slamon DJ: Cancer biology, Editorial overview. Current Opinion in Oncology 4:124-126, 1992.

2. Hawkins RA, Hoh C, Dahlbom M, Choi Y, Glaspy J, Tse N, Slamon D, Chen B, Messa C, Maddahi J, Phelps ME: PET Cancer Evaluations with FDG. J Nuclear Med 32:1555-1558, 1992.

3. Wilson CA, Slamon DJ: Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways. Journal of the National Cancer Institute, Vol. 97, No. 17. Sept. 7, 2005.